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Introduction
Functional losses associated with ESRD
The three main functions of the kidneys are i) removal of water-soluble waste 
substances from the blood, ii) production of various hormones regulating blood 
pressure and red blood cells generation and iii) homeostasis of body fluids, pH, and 
electrolytes. Chronic kidney disease (CKD) is a syndrome due to the progressive 
loss of renal function. Several diseases cause CKD, the most common being related 
to hypertension, atherosclerotic disease, type 2 diabetes and chronic 
glomerulonephritis. CKD can be quantified in 5 levels according to renal function 
estimated on the bases of age, gender, ethnicity and creatinine level1. Symptoms 
associated to CKD may be even undetectable until the highest level of CKD, close to 
the time to start renal replacement therapy. The proportion of people affected by 
different levels of CKD is very high, up to 10% depending from the age structure of 
the population and socio-economic factors. However, because it is often 
paucisymptomatic, the clinical detection is difficult and some countries tested pilot 
projects aimed to improve the detection of CKD patients and their referral to the 
adequate therapy, with the main aim to prevent the development to end-stage renal 
failure2-4.
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Renal Replacement therapy (RRT)
RRT can be delivered as peritoneal dialysis, obtained by infusion of buffered osmotic 
solution of electrolytes or by extra-corporeal treatment, including hemodialysis and 
convective modalities such as hemodiafiltration (HDF).  
Hemodialysis is the most commonly used modality of renal replacement therapy 
(RRT) for patient with ESRD. The procedure is able to remove waste/toxic 
substances, balance electrolyte composition of the body fluids, normalize blood pH 
and remove the fluids accumulated between two hemodialysis sessions. 
Hemodialysis is usually performed 3 times a week for approximately 4 hours each
session. The centre-piece of the process is a semipermeable dialysis membrane. On 
one side, inside capillaries, the blood of the patient flows at a rate between 250-400 
mL/min, on the other side, an ultra-pure solution of electrolytes buffered with 
bicarbonate and acetate at a slightly basic pH moves counter-flow at a rate of 500 
mL/min. Blood is continuously drained and returned from a vascular access, which 
could be a native artero-venous fistula or graft, or a catheter. 
The previously described renal replacement functions are realized through two 
mechanisms driven by difference in concentration of solutes and by differences in 
the hydraulic pressure on the two sides of the dialysis membrane. Small molecular 
weight substances such as urea are mainly removed with the first mechanism, 
namely diffusion, while those of medium molecular weight are removed mainly by 
convection. HDF combines the conventional diffusive mechanism of hemodialysis 
with the convective mechanism of hemofiltration. Accordingly, this method is able to 
couple optimal small molecular clearance with the clearance of larger molecules 
clearance, making it the dialysis treatment with the highest performance. With the 
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development of techniques for on-line production of sterile infusate from dialysate5, 
HDF has become cheaper and potentially more widely applicable. Extra-corporeal 
RRT is increasingly safer and better tolerated. However, life expectancy is still 
significantly lower than in age-gender matched subjects from the general population.
Protein energy wasting 
The unsatisfactory outcome of patients on dialysis is mainly due not only to the high 
prevalence of cardiovascular risk factors (hypertension, dyslipidemia, smoking, 
advanced age and diabetes mellitus) but also to the high prevalence of uremia 
related risk factors (fluid overload, hyperphosphatemia, high calcium-phosphate 
product, anaemia, left ventricular hypertrophy, inflammation, oxidative stress, 
endothelial dysfunction, insulin resistance, excess sympathetic tone, 
hyperhomocysteinemia, high level of lipoprotein (a) and increased asymmetrical 
dimethylarginine concentration)6,7. In addition, the frequent use of catheters as 
vascular access, mainly at initiation of hemodialysis has been associated with an 
enhanced inflammatory state.  In patients with advanced CKD multiple metabolic and 
nutritional derangements, generically defined as malnutrition, have been reported8.
More recently, the term ‘‘malnutrition’’ has been replaced by ‘‘wasting’’ in recognition 
that the disorder cannot be corrected by simply increasing dietary nutritional intake.
The International Society of Renal Nutrition and Metabolism defined protein energy 
wasting according to the presence of at least three out of the following four 
characteristics9: (1) abnormal levels of circulating biomarkers (low serum albumin, 
pre-albumin, or cholesterol concentrations); (2) decreased body mass (low or 
decreased body mass or fat mass, or weight loss with decreased protein and energy 
intake); (3) decreased muscle mass; and (4) abnormal nutritional score.
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Traditionally, an important component in the assessment of nutritional status in 
chronic patients is the evaluation of body weight or body mass index (BMI)10. 
However, it is well known that BMI is not capable to differentiate between fat, muscle 
and bone, or body fat distribution (abdominal vs. peripheral). Recently, Rodrigues et 
al11 found that BMI thresholds do not accurately diagnose adiposity in elderly on 
hemodialysis. The conclusion is that considering only BMI as marker of nutritional 
status carries a high risk of misclassification, explained by the changes of body 
composition along the natural aging process (such as an increase in fat mass and 
decline in muscle mass), probably accelerated by the presence of a chronic disease 
such as CKD.
Physical methods for evaluating the nutrition status of hemodialysis patients
Nutrition status assessment is made on the basis of anamnesis, physical 
examination, evaluation of nutrient intake, and on a selection of various 
screening/diagnostic methodologies.
These methodologies can be subjective, e.g. the Subjective Global Assessment 
score (SGA)12, or objective in nature (e.g. bioimpedance analysis (BIA))13. In 
addition, certain biochemical tests may be employed (e.g. albumin, pre-albumin)14.
There are several different types of bioimpedance methods available today, and the 
results may vary depending on which type is applied. This may vary from mono-
frequency BIA methods, using either vector plots or empirical equations used to 
convert measured impedances into clinically meaningful information, to 
Bioimpedance spectroscopy without a physiological model using multiple 
frequencies to estimate body fluid  compartments. It is assumed that the latter
provide a more precise assessment of the extracellular and total body water15. 
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However, very large databases providing normal values for vectors in the general 
population and in dialysis patients have been published16 and both phase angle and 
vector length have been shown to be higly predictive of survival17.
Finally, a more recently validated physiological model18 facilitates separation of the 
body into three essential compartments, lean body mass, adipose tissue mass, and 
fluid overload (3 compartment [3C] model). The bioimpedance spectroscopy method 
with a physiological model is a promising practical method that may allow the 
diagnostic separation necessary for the diagnosis of protein energy wasting in CKD 
patients.
However, there are still limited data regarding the value of this model in the clinical 
assessment  of ESRD patients. In chapter 2, an overview is given on different 
methods to assess body composition and protein energy wasting in dialysis patients.
‘Reverse epidemiology’ paradox 
Several parameters related to inflammation, malnutrition and presence of various 
cardiovascular diseases have been established as major risk factors for mortality 
and morbidity in patients on renal replacement therapy. Nutritional problems, 
including loss of appetite and decrease of body weight can be present also in the 
phase before the need for initiating renal replacement therapy. Some of these risk 
factors, i.e. low albumin and high C-reactive protein (CRP) levels, have similar 
behavior in patients on dialysis as well as in the general population, but others show 
a different relationship with outcome. On the contrary than in the general population, 
higher blood pressure levels19 and obesity10 are associated with better survival in 
patients on chronic hemodialysis. This observation produced a list of publications
under the umbrella of the term ‘reverse epidemiology’. Specifically, obesity as 
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defined by higher BMI in dialysis patients is associated with better outcome10. This 
paradoxical benefit of obesity has been shown to exist also for patients with a wide 
range of cardiovascular diseases as coronary artery disease, hypertension, 
peripheral vascular disease, atrial fibrillation and aortic stenosis, and for patients with 
coronary bypass cardiac implants and other acute coronary syndromes20-26. The 
obesity paradox has been specifically demonstrated in heart failure patients with a 
consistency of results seen among a wide range of clinical subpopulations across 
geographical locations, gender, age range, and the presence or absence of 
comorbidities27, and across different measures of body fatness, but mainly BMI.
Most of the data concerning the obesity paradox in dialysis patients are derived from 
US populations28. However, European data are lacking so far, which is of importance 
given the fact that various risk factors may differ between populations. As an 
example, the cardiovascular risk profile is completely different between US, Northern 
and Southern European populations29. In chapter 3, the relation between BMI  and 
survival was investigated in a larger cohort of Southern European dialysis patients. 
However, as mentioned previously, BMI does not differentiate between fat and lean 
body mass. Therefore, it is not possible to recognize which component of body 
composition is related to better survival, either fat or lean tissue mass or both. For 
this reason, in order to clarify the paradox, is fundamental to further distinguish 
between main body components, for which the novel 3-C bioimpedance model 
appears to be a promising clinical tool. However, the prognostic value of fat mass 
and lean tissue mass expressed by this method with regard to survival has not yet 
been validated.  In chapter 4, the relation between body compartments expressed by 
the 3-C bioimpedance method with outcome was assessed in a larger international 
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cohort of dialysis patients. In this chapter, also the relation between BMI with fat and 
lean tissue mass was assessed.
The effects of starting dialysis on nutritional parameters 
As reported by Pupim et al,30 the progression of renal insufficiency is associated with 
the development of protein-caloric malnutrition. At the initiation of renal replacement 
therapy inflammation, metabolic acidosis, and impaired insulin/insulin-like growth 
factor functionality are often already present and all of them negatively affect protein 
anabolism even in presence of an adequate nutritional intake31. In patients with 
advanced kidney disease, metabolic and nutritional derangements induced by 
uremia interact and reinforce each other in a deleterious vicious circle. Based30 on 
this evidence, some investigators have advocated the initiation of renal replacement 
therapy before the development of malnutrition32-34. Whereas the start of dialysis with 
the increased clearance of uremic toxins may lead to an improvement in nutritional 
state by an increase in appetite and wellbeing resulting from the improvement in the 
uremic state, the interference of dialysis with regular meals, the loss of proteins and 
amino acids in the dialysate, and the catabolism resulting from the dialysis treatment 
may negatively affect nutritional state30,35. Ikizler et al36 showed that a dialysis 
session is a catabolic event and leads to a net loss of protein stores. However, 
longitudinal survey of the nutritional effects of dialysis treatment showed that 
hemodialysis per se improves body protein metabolism, which may be due to the 
clearance of uremic toxins counterbalancing the catabolic effects of hemodialysis. 
Using a leucine kinetic study before and 8 to 10 weeks after initiation of dialysis 
treatment in incident patients maintained on an unchanged diet, Lim, Yarasheski, 
and Flanigan37 observed after initiation of dialysis treatment an increase in protein 
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synthesis. Therefore, the benefit may be above and beyond the potential catabolic 
effect that dialysis has38. However, literature addressing the effect of dialysis 
initiation on changes in nutritional parameters and body composition is limited and 
contradictory and some other investigators30 support the alternative policy to delay 
the initiation of dialysis therapy until clear uremic symptoms are present, with the aim 
to postpone the catabolic process induced by dialysis and the high mortality rate 
detected in the first weeks/months of treatment36,39-43.
Finally, it has to be considered that Patients undergoing a chronic haemodialysis 
programme often need to be admitted to hospital mainly because of vascular access 
complications, infections and cardiovascular diseases44. When patients are admitted 
to hospital, a significant weight loss is often observed, which is probably a sign of 
progressive malnutrition45-47. According to Borrego et al47, body weight loss was 
already observed at discharge, and continued progressively for at least 4 weeks after 
the hospital stay. This weight loss was not sex- or age-dependent, but was related to 
the length of the hospital stay, and the presence of hypoalbuminemia, which is 
probably a sign of inflammation during hospital stay. Many factors are involved in this 
malnutrition47, and the decrease caloric and protein intake play an important role. 
The cause can be illness-related anorexia and the general low level of appreciation 
of the hospital food48,49. On the other hand, inflammation- and prolonged fasting 
related protein catabolism also cause mobilization of protein reserves, especially 
from muscles, as occurs in patients who have been in the intensive care unit for a 
long period of time or in difficult post-operative recoveries50.
Accordingly, following the start of dialysis treatment in chapter 5, changes in body 
composition and the effect of possible determinants on these changes, were 
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investigated and in chapter 6, the course of two nutritional biomarkers, serum 
albumin and creatinine was analyzed.
Inflammation and malnutrition 
Loss of muscle mass, a common feature of many inflammatory disorders, is 
considered one of the most important markers of protein energy wasting in CKD51. 
According to Roubenoff52, subclinical chronic inflammation is an important 
component of the pathophysiology of muscle wasting. Pro-inflammatory cytokines, 
such as IL-6 and tumor necrosis factor (TNF), stimulate the breakdown of muscle 
protein53. The close association between muscle wasting IL-6 and CRP in previous
studies performed in CKD patients54,55 suggests that systemic inflammation is 
involved in muscle wasting also in patients with advanced CKD. Various biomarkers 
have been proposed to measure systemic inflammation and, given the expenses 
associated with regular IL-6 or CRP monitoring,  recently neutrophil to lymphocyte 
ratio has been proposed as easily available, cost-efficient indicator56-58. However, the 
relation between the neutrophil to lymphocyte ratio and other biomarkers of 
inflammation, such as CRP, as well as serum albumin have not been investigated 
yet. In chapter 7, the relation between the neutrophil to lymphocyte ratio, CRP and 
serum albumin was investigated.
Hyponatremia, inflammation and nutritional state
Another marker which may be related to the nutritional state of the patient is the 
serum sodium level. 
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Hyponatremia, defined as a concentration of serum sodium levels below 135 
mMol/L, is a common electrolyte disorder associated with increased mortality in
general population60-62. The worse prognosis associated with hyponatremia is more 
pronounced in certain populations: women, postsurgical patients, patients with 
cirrhotic and cardiac failure63-65, and remains even in people with hyponatremia at 
moderate levels, that is 130-134 mMol/L.
Patients with chronic kidney disease also have a high prevalence of hyponatremia, 
estimated in the range of 13.5%66. Whereas well-functioning kidneys can prevent 
hyponatremia in the general population, in patients with advanced CKD, the 
protection from this risk dissolves in connection with the loss of residual renal 
function. After HD initiation, the balance of sodium and water occurring during 
dialysis sessions appears as a new potential factor in the development and 
maintenance hyponatremia. Hyponatremia may also be associated with 
inflammation, likely for the so called sick cell syndrome67,68, a disorder of the cellular 
Na+/K+ pump with several causes which include hypoxia, sepsis, hypovolaemia and 
malnourishment.
As in the general population, in patients on dialysis hyponatremia is also associated 
with increased risk of death69-73. These studies found that low pre-HD sodium is 
associated with diabetes, neurological and psychiatric diseases and greater inter-
dialysis weight gain. In HD patients, it is unclear whether the relationship between 
hyponatremia and mortality is causal or explanatory of some associated cofactor. 
However, the association between hyponatremia and impaired cerebral function is 
clearly demonstrated65,74. It has been suggested that hyponatremia is associated 
with a “frail phenotype”, given its association with low body mass index (BMI) and 
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biochemical markers of malnutrition 69,70,75. In other patient populations, such as
patients with cirrhosis or heart failure additional associations with malnutrition75,77,78, 
abnormalities in fluid status75,78,79 or with inflammation67 have been detected. 
However, these associations, have not yet been investigated systematically in 
dialysis patients. One of the reasons is the absence of a routine evaluation of the
inflammatory status, i.e. by monitoring C-reactive proteins. As a consequence, the 
interpretation on the causative nature of the relationship between hyponatremia and 
outcome still remains unclear. For this reason, in chapter 8, the relation between 
hyponatremia with body composition, fluid overload  and inflammation was 
investigated, as well as the relation between hyponatremia and outcome after 
correction for these parameters.  
In chapter 9, the main results of the thesis are outlined in a general discussion 
Aim of the thesis
In summary, with the exception of the Asian patients, patients on maintenance 
hemodialysis the relationship between body mass index and mortality is often the 
reverse of the normal association. Accordingly, do we have to question the 
appropriateness of target levels for BMI as well as other main measures (i.e. blood 
pressure) used to assess patient on dialysis? We believe that the correct answer 
should deal with the causes for the observed reversed epidemiologic relations, and 
for this reason the major aims of this thesis are a) to clarify the paradoxical 
observation of the improved survival in obese patients on chronic hemodialysis, and 
to assess the relation between body composition with outcome in more detail b) to 
study the development of nutritional biomarkers as well as body composition after 
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admission to RRT, c) to investigate the relationship between nutritional status, 
hyponatremia and inflammation.
Outline of this thesis
In chapter 2, in a Southern European HD population the relationship between 
survival and BMI at the start of HD treatment is examined, as is the influence of body
weight variations during the first year of treatment. Chapter 3 provides an overview 
of the different nutritional markers and the available methodologies for the physical 
assessment of nutrition status in hemodialysis patients, with special emphasis on 
early detection of protein energy wasting.
Chapter 4 and chapter 5 focus on changes in nutritional parameters following the 
start of dialysis. In chapter 4, changes in body composition, assessed by the 3-
compartment bioimpedance model are studied. 
Serum albumin and creatinine levels are indicators of both nutritional status and of 
mortality risk in hemodialysis patients. In chapter 5 changes and determinants of
these nutritional indicators in the 2 years following the first 3 months of hemodialysis
are examined.
Inflammation likely plays an important role in the pathogenesis of muscle wasting in 
CKD. C-reactive protein, an acute-phase reactant, has emerged as the most 
widespread inflammatory biomarker for clinical use but it’s use is limited by the costs 
of the methods. The neutrophil lymphocyte ratio has been proposed as an alternative 
and cost-effective marker for inflammation. The aim of the study reported in chapter 
6 was to evaluate to which extent neutrophil lymphocyte ratio correlated with C
reactive protein and serum albumin levels. Furthermore, it was aimed at determining 
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whether the combination of inflammatory markers (neutrophil lymphocyte ratio and 
albumin levels) improves prediction of C reactive protein levels in chronic HD 
patients. The association between hyponatremia and mortality has also been 
observed in patients with acute and chronic diseases, such as ESRD, congestive 
heart failure, pulmonary embolism and myocardial infarction. It has been suggested 
that hyponatremia is associated with a “frail phenotype”, given its association with 
low body mass index (BMI) and biochemical markers of malnutrition.
Concerning the problem of reverse epidemiology, In chapter 7, body composition 
assessed by MF-BIS, using the 3-C physiological model, was used to explore the 
relationship between lean tissue, fat tissue, and survival.
Given the relation between hyponatremia with outcome in dialysis, the study 
reported in chapter 8 aimed to explore the relationship between hyponatremia, 
nutrition, inflammation and fluid status. The primary goal was to determine predictors 
of hyponatremia, including biomarkers of inflammation, fluid status and malnutrition. 
The secondary goal was to assess the association between hyponatremia and 
mortality with appropriate adjustments for malnutrition, fluid status and inflammation.
The thesis ends with a summary and general discussion of the results in in chapter 
9.
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Abstract
Background
In the general population, a high body mass index (BMI) is associated with increased cardiovascular 
disease and all-cause mortality. However, according to US epidemiological evaluation in maintenance 
haemodialysis (HD) patients, a reverse epidemiology is described and baseline obesity appears 
paradoxically associated with better survival. The aim of this study is to examine in a Southern 
European HD population the relationship between survival and BMI at the start ofHD treatment, and 
how survival is influenced by the bodyweight (BW) variations during the first year of treatment.
Methods
A total of 85 dialysis centres located in Portugal, France and Italy and belonging to the FME European 
dialysis chain were included. The current prospective analysis focuses on incident patients admitted 
to these centres between 1 January 2000 and 30 September 2005 with <1 month of previous follow-
up on RRT. Data were gained from the FME EuCliD database. Patients were classified at baseline in 
four categories according to the BMI: underweight, normal range, overweight and obese. Also, the 
patient survival was analysed according to five quintiles of BW changes during the first year 
ofHDtreatment<−5.8%, −5.8 to −1.1%, −1.1 to 1.7% (reference category), +1.7 to +5.5% and >+5.5%. 
Survival analysis was adjusted for a set of demographic and comorbids using Kaplan–Meier curves 
and Cox model. Hazard ratios and their 95% confidence intervals were calculated with the use of the 
estimated regression coefficients and their standard errors.
Results
A total of 5592 patients were analysed (40.9% females), and the mean age at admission was 
64.4+16.5 years. Of them, 27.7% were diabetic. The mean follow-up was 2.0 ± 1.6 years. Almost half 
of the patients (46.4%) were in the normal range of BMI (20–24.9 kg/m2). When analysed with the 
Cox model, the categories of baseline BMI (underweight, normal range, overweight and obese) 
significantly influenced the survival with the respective hazard ratio (HR) and confidence interval at 
1.14 (0.96–1.35), 1, 0.74 (0.67–0.9) and 0.78 (0.56–0.87). The strength of the association as well as 
the shape of the curve remains unchanged after considering age, diabetes and comorbidities. 
Moreover, when compared to patients for whom BW remained stable during the first year of HD 
treatment, survival was significantly lower in patients presenting in the lower quintile of BW variation 
(<−5.8% in 1 year) with an HR of 1.6.
Conclusions
Despite increased comorbidities, overweight and obese patients on maintenance HD carry a 
significant lower mortality risk than patients in the normal and lower BMI ranges. This confirms the 
reverse epidemiology previously reported in US HD patients for these categories of BMI. Also BW 
variation during the first year of HD treatment is associated with patient survival, highlighting the 
importance of nutrition in this setting.
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Introduction
In the general population, being overweight and obese is found to be associated with 
the increased prevalence of cardiovascular disease and overall causes of mortality1. 
However, in haemodialysis (HD) patients, an unusual relationship between body 
mass index (BMI) and survival was reported for the first time almost 25 years ago2
with increased mortality in patients with low BMI and no increased mortality in 
overweight and obese HD patients.
More recently, this association was reported in US HD patients, showing an inverse 
linear relationship between survival and BMI, that is a survival advantage, even in 
morbidly obese patients3. Also, since the Diaphane study, the DOPPS study has 
reported this type of relationship in a set of US and European patients4. This inverse 
and unexpected correlation is part of the recent concept called reverse 
epidemiology, reported also for instance with predialysis blood pressure5 and that 
has been thoroughly reviewed6. Nevertheless, the inverse relationship between BMI 
and survival in HD patients is not universally recognized.
Several studies have failed to find this association in Asian patients like in Japan7 or 
among Asian American HD patients8,9. The first objective of our study was to 
examine the relationship between BMI and survival in Southern European incident 
HD patients whereby the case-mix of the dialysis population has changed 
dramatically since the DIAPHANE study and because the epidemiology of 
cardiovascular disease and especially coronary artery disease (CAD) is dramatically 
different between the US and Northern and Southern Europe10. The second 
objective was to evaluate the effect of the bodyweight (BW) variation during the first 
year of HD treatment on the prognosis of maintenance HD patients.
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Patients and methods
This prospective study included 76 dialysis centres owned by Fresenius Medical 
Care (Bad Homburg, Germany) in Italy, Portugal and France (see the Appendix). All 
incident end-stage renal disease (ESRD) patients, with less than 1-month previous 
HD treatment in another facility, were included in the study between 1 January 2000 
and 30 September 2005. Amputated patients were excluded from analysis in order to 
avoid miscalculation of BMI. Data were retrieved from the EuCliD (European Clinical 
Database) database that is updated monthly with patient characteristics including 
demographics, comorbidities, dialysis prescriptions, ancillary therapies, lab results 
and outcome. At the start of HD, the patients were categorized into four categories of 
BMI: BMI <20, 20–24.99, 25–29.99 and >30 kg/m2. The upper two categories 
corresponded to the WHO standard classification of overweight (25–29.99 kg/m2) 
and obese (≥30 kg/m2).
According to the general acceptance and also in order to have meaningful numbers, 
a BMI <20 was defined as being underweight, and BMI =20–24.99 was considered 
to be normal weight. The comorbid conditions present in the study were defined 
according to the International Classification of Diseases, tenth revision code (ICD-
10): CAD (I20-I25, Z95.1, Z95.5), heart failure (I50-I51, I13-I13.2, I42-I42.2, I42.6-
I42.7, I11.0, I11.9, I97.1, I97.8, I42.9, I43.2), valvular heart disease (Z95.2, Z95.3, 
Z95.4, Z95.9, I01.1, I05.0, I08.9, I09.1, I09.8, I33.0, I38, I39.8, T82.0, Z48.8, Z95.9, 
T82.6, I45.2, I45.3, I45.6-I47.9, I49.3-I49.9, I44.1-I44.3, I48, I49.0, I34-I37.9, I39-
I39.4), atherosclerosis disease (I70-I76.9), cerebrovascular disease (I60-I69), 
pulmonary disease (J41-J47.9, J96), depression (F32.1-F33.9, F06.3, F20.4, F25.1, 
F31.3, F31.9), cancer/neoplastic disease (C0-C97.9, D37-D48.9) and severe liver 
disease (K70-K77.9).
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Distribution of comorbidities was analysed in each BMI category and according to 
age (below and above the age of 65). Survival was studied among the different BMI 
ranges and adjusted for the different comorbidities.
Also, survival from the second year of treatment has been analysed according to the 
evolution of the BW during the first year of HD treatment.
Patients were split into five quintiles according to this evolution expressed as a 
percentage normalized to the ideal BW (calculated from the Broca formula: ideal BW 
= (height in cm − 100) for males and ideal BW =(height in cm − 104) for females11): 
<−5.8%, −5.8 to −1.1%, −1.1 to 1.7% (reference category), +1.7 to +5.5% and 
>+5.5%.
Statistics
The mean values and frequencies of the parameters were compared by ANOVA or 
the chi-square test, as appropriate. Survival functions according to baseline BMI 
were described using the Kaplan–Meier technique. The log-rank testwas used for 
univariable comparisons.Cox proportional hazard models were used to compare 
survival according to baseline BMI adjusting for a set of demographic and 
comorbids.
All analyses were performed with adjustment for age, gender and for each of the 
following comorbidity indicators: diabetes, CAD, heart failure, valvular heart disease, 
atherosclerosis disease, cerebrovascular disease, pulmonary disease, depression, 
cancer/neoplastic disease and severe liver disease (Table 1). Only age has been 
introduced as a continuous variable, and all others as categorical variables (for 
gender: ref. females; for comorbidity indicators: ref. present/absent). Both Kaplan–
Meier curves and Cox model used the same end-point (death), and patients were
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censored when they were changed to peritoneal dialysis therapy, were transferred to 
another dialysis unit, received a kidney graft or were still on extra-corporeal 
treatment on the final observation date (30 September 2005). All patient 
characteristics considered in the study were reported.
When Cox proportional hazard regression was applied, all reported variables were 
used to obtain the final multivariate model. Estimated relative risks (hazard ratios) 
and their 95% confidence intervals (CI) were calculated with the use of the estimated 
regression coefficients and their standard errors. The contribution of covariates to 
explain the dependent variable was assessed by means of a two-tailed Wald test, 
with P < 0.05 considered significant. The proportion hazard assumption was checked 
for each model by inspection of the complementary log minus log plots. To evaluate 
the impact of the BW changes on mortality, patients surviving more than 1 year were 
selected. The behaviour of BW during the first year was evaluated, classifying the 
patients according to decrease or stability and the increase of dry BW. Then, survival 
analyses were modelled considering the behaviour of BW change during the first 
year of follow-up as a predictor of subsequent mortality. All statistical analyses were 
performed using the SPSS software, version 14 (SPSS Inc., Chicago, IL, USA).
Results
A total of 5592 patients were included in the study during this 57-month period. The 
average age was 64.4 ± 16.5 years and the mean follow-up 2.0 ± 1.6 years. Female 
gender represented 40.9% of the whole population. However, in obese patients, the 
proportion of female gender increased significantly (Table 1).
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The prevalence of diabetes was 27.7%, but the distribution of diabetic patients 
increased significantly in the overweight and obese BMI category (Table 1). The 
distribution of BMI among the studied patients is also shown in Table 1. Almost half 
of the patients (46.4%) were in the normal range of BMI (20–24.99 kg/m2). A BMI 
<20 (underweight category) was present in 13.9% of the patients. Overweight (BMI = 
25–29.99 kg/m2) and obese (≥30) represented 28 and 11.7%, respectively. The 
prevalence of CAD was equally distributed in the different BMI ranges in 
maintenance HD patients over the age of 65. In younger patients below 65, CAD 
increased in overweight and obese patients compared to normal and underweight 
patients (Figure 1).
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The heart failure prevalence was significantly higher in the obese patients when 
compared to normal BMI patients, both below and over 65 years of age. The other 
BMI categories were not significantly different for the prevalence of this comorbidity.
The proportion of patients who were transplanted was 6.6% ranging from 5.2% in 
underweight to 7.3% in the normal range. The proportion of those transferred to 
peritoneal dialysis was 9.4% ranging from 8.9% in overweight to 10.6% in 
underweight. The total number of deaths during the follow-up was 1147 (23.5%). The 
Kaplan–Meier survival curve for the four BMI ranges is displayed in Figure 2.
Survival was significantly better for overweight and obese patients compared to that 
for normal and underweight patients. In Figure 3 and Table 2, the unadjusted and 
adjusted relative risks of death are displayed for the four BMI categories, with the 
normal BMI range used as a reference. Overweight and obese patients had an 
adjusted hazard ratio of 0.78 (0.67–0.9) and 0.71 (0.56–0.87), respectively.
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The second part of the study was the report of survival according to the evolution of 
the BW during the first year of HD treatment. The patients were divided into five 
categories according to the quintile distribution: <Ѹ5.8%, Ѹ5.8 to Ѹ1.1%, Ѹ1.1 to 1.7% 
(reference category), +1.7 to +5.5% and >+5.5%. Table 3 reports the patient 
characteristics and the patient outcome of the studied population including the 
adjusted hazard risks and the corresponding 95% CI. Mortality was significantly 
higher in the lowest quintile, in patients who had a weight loss over 5.8% during the 
first year of HD treatment, whereas it was not influenced in other quintiles, in patients 
with a weight loss lower than 5.8%, or who remained stable or gained weight.
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Discussion
In this study, we confirm among a large prospective Southern European cohort of 
incident HD patients that a high BMI range in the overweight and obese is 
associated with better survival than in normal and underweight BMI categories. This 
unexpected relationship between BMI and survival had been previously suggested in 
French patients in 1982 by Degoulet et al.2 in the DIAPHANE study. It was confirmed 
later by Fleischmann et al.12 using different BW ranges, showing a clear survival 
advantage in patients with a BMI >27 kg/m2, mostly in African American patients. 
Our findings in an incident HD patient cohort are close to what has been reported in 
incident8,13 and prevalent US patients3. These latter reports used different categories 
of BMI, from simple (three ranges:<23.1, 23.1–27.8, >27.8 kg/m2)13 to very 
sophisticated distribution (from <18 or 19 to >37 to 45 kg/m2 in 8 to 11 
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categories8,14). The other studies2,4,13 did not analyse specifically the issue of the 
morbidly obese patients.
Our analysis was not able to confirm the survival advantage in morbidly obese 
patients, as reported by Kalantar-Zadeh et al.14 because the number of patients in 
this category (BMI>40 kg/m2) was too small (0.7% of the total patients) and they 
were pooled with the 30–39.99 kg/m2 category.
Moreover, we report in the incident patients the distribution of severe comorbidities 
such as diabetes, CAD and heart failure. Adjustments for these comorbid conditions, 
absent in the Kalantar-Zadeh study14, did not change the paradoxical relationship 
between BMI and patient survival. It confirms the findings of the DOPPS study4 in 
which obese and overweight patients with high-risk comorbidities were found to have 
better survival than low and normal BMI patients with the same risk profile.
Studying the mortality among a cohort of Spanish HD patients, Marcen et al.15 did 
not find any difference of BMI between the patients who survived and who died.
However, in this prevalent cohort, the relationship between BMI and survival was not 
studied independently and was not adjusted for other factors such as age, vintage 
and comorbidities.
More surprisingly, the Dutch NECOSAD study did not find advantages of a high BMI 
on the survival of incident female and male HD patients16, whereas it reports the 
expected increased mortality risk in the low range of BMI (<18.5 kg/m2). However, 
this study only included patients between 50 and 65 years of age and used a BMI
reference range of 22.5–25 kg/m2. Even when these criteria are applied to our 
studied population, it does not change our findings and does not explain the 
discrepancy between the Dutch and Southern European dialysis patients regarding 
survival and BMI ranges. The explanation may be related to the difference of 
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cardiovascular disease epidemiology between the Netherlands and Southern 
Europe. As reported by Levy and Kannel10, the death rate from CAD in both sex and 
in the age range 35–74 is much lower in France, Spain and Portugal (three of the 
four countries involved in the current study) when compared to the Netherlands. A 
higher prevalence of cardiovascular disease in Dutch obese HD patients may blunt 
the survival advantage observed in Southern European obese HD patients, 
especially because young patients, aged between 18 and 50 years, were not 
included in the Dutch study. The high prevalence of cardiovascular disease in the 
studied age ranges may have outweighed the benefit of a high BMI.
We have also confirmed that a BW loss >5.8% (first quintile) during the first year of 
HD treatment was associated with significantly increased mortality. The second 
quintile (Ѹ5.8 to Ѹ1.1%) had no significant reduction in survival, whereas Kalantar-
Zadeh et al.14 reported that each category below Ѹ1% of BW loss had a significant 
increase in patient death. In this last study, prevalent patients were analysed
whereas our cohort included only incident ones. Previous reports have shown a 
different evolution of BW in both prevalent and incident cohorts. In the HEMO 
study17, prevalent HD patients displayed a progressive decline of BW all along the 3-
year follow-up, whereas in patients starting HD18,19, BW initially decreased during the 
first 2–4 months corresponding to the fluid removal and then increased again 
because of appetite recovery. Whereas in prevalent patients BW loss is mainly 
interpreted as progressive malnutrition, in incident patients it is possible that fluid 
removal for extracellular volume accumulated in the pre-dialysis period may interfere 
with the interpretation of the BW variation during the first year of treatment. This may 
explain why only an important BW loss >5.8% in incident HD patients is found to 
have a detrimental effect regarding survival, similar to other nutritional markers such 
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as serum albumin and prealbumin whose lowest quartiles were associated with a 
higher mortality rate in a study by Combe et al.20.
Trying to explain this paradoxical association of obesity with better survival among 
HD patients, Johansen et al.8 ruled out from their data the influence of lean body 
mass and inflammation suggesting that fat itself might be protective in the catabolic 
condition of HD treatment. For Kwan and Beddhu21, the paradox is related to the 
balance between the deleterious effect of adipose tissue (inflammation, increased 
associated comorbid conditions, . . .) and the nutritional advantage of adiposity 
represented by fat tissue in the catabolic situation of HD treatment. Another 
hypothesis is raised by Sarkar et al.22. They have shown that the visceral 
compartment, also referred to as the high metabolic rate compartment, is inversely 
related to the BMI and is correlated with the protein catabolic rate, a surrogate of 
uraemic toxin generation. The interpretation is that patients with low BMI have a 
relatively higher production of uraemic toxins than high BMI patients, leading to 
decreased survival by higher or increased dialysis needs. However, this appealing 
hypothesis cannot be the unique explanation since reverse epidemiology for BMI 
also exists in other fields, like heart failure for instance23. Moreover, it has been 
recently reported that the reverse epidemiology concept regarding pre-dialysis blood 
pressure is time dependent24 with an increased mortality risk associated with the low 
blood pressure level in the first 2 years of dialysis treatment followed by an increased 
risk of mortality associated with high blood pressure from the third year of HD 
treatment. This time-dependent relationship between BMI and mortality may exist but 
remains to be confirmed.
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That was not the case in the NECOSAD study in which the 7-year follow-up did not 
display any change in the relationship of BMI and survival, both in HD patients and 
normal subjects16.
In conclusion, we confirm the reverse epidemiology regarding BMI and survival in 
incident Southern European HD patients even after adjustments for comorbidities, 
except in the case of morbid obesity. Also, it is confirmed that loosing weight during 
the first year of HD treatment is associated with an increased mortality risk. This
stresses the pivotal role of nutritional issues in dialysis patients, and strengthens the 
need for the regular assessment of nutritional markers and nutritional intervention 
studies.
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Appendix
Participating Centres: France
Centre de Rein Artificiel de Tassin, Centre Hemodialyse du Languedoc 
Mediterranee, Centre Nephrologique D’Occitanie (CNO), Saint Simon, La Vall´ee, 
CRAT Montalieu, CRAT Rillieux, CRAT Unite d’Autodialyse (Chateau), Centre 
d’Autodialyse du Lunel, Centre Hemodialyse du Beziers, C.T.S.I.R., C.H.L.M. Nimes, 
DIALYTEC, Fondial Fontenay sous Bois, Fondial Vincennes, Fondial Champigny, 
AERA—Gennevilliers,
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AERA—Pontault Combault, AERA—Villejuif.
Participating Centres: Italy
NephroCare Dialnova, NephroCare Nephros Cassino, NephroCare Centro Dialisi 
Riviera del Conero, NephroCare Nefrosal, NephroCare Mirabial, NephroCare 
Malpighi, NephroCare Sodial, NephroCare Emodial Vesuvio, NephroCare SM2, 
NephroCare Emodial, NephroCare Nephros Venafro, NephroCare Alfadial, 
NephroCare Dialcenter, NephroCare Cilento Dial Dianoval, NephroCare Kidney, 
NephroCare Nefrodisal, NephroCare Cilento Dial Olidial, NephroCare Renal Center, 
NephroCare Nedial, NephroCare Nedial Napoli, NephroCare Cercos, NephroCare 
Beta Dial, NephroCare Rusdial, NephroCare Omnia Dial, NephroCare Dial Torre, 
NephroCare Fanus c/o Clinica Ruesch, NephroCare Enne E, NephroCare Fanus 
Somma Vesuviana, NephroCare Dialten, NephroCare Ruscosa, NephroCare Dialy 
Center, NephroCare Il Nefrologico, NephroCare Centro Diagnostico e Terapeutico 
delle Malattie Renali.
Participating Centres: Portugal
Abrandial – Clinica de Doenc¸as Renais, FMC—Amadora, Centro Medico Nacional –
Clinica de Beja, Braga, Cancho, Almada, FMC-NMC Centro Medico Nacional, FMC 
Entroncamento, FMC Centro de Hemodialise de Evora, Centro de Hemodialise de 
Fafe, FMC – Clinica Hemodialise de Faro, Egidial, FMC Lumiar, FMC Restelo, FMC 
– Ponte da Barca, FMC-NMC Centro Medico Nacional Portimao, Ribadial – Clinica 
de Dialise de Santarem, FMC Setubal, Tavira, FMC Torres Vedras, Hemodial – Vila 
Franca Xira, Vila Nova de Gaia, Visodial – Centro de Dialise de Viseu, Tagus Dial.
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Abstract
This article aims to provide an overview of the different nutritional markers and the available 
methodologies for the physical assessment of nutrition status in hemodialysis patients, with special 
emphasis on early detection of protein energy wasting (PEW).
Nutrition status assessment is made on the basis of anamnesis, physical examination, evaluation of 
nutrient intake, and on a selection of various screening/diagnostic methodologies. These 
methodologies can be subjective (e.g. the Subjective Global Assessment score (SGA)) or objective in 
nature (e.g. bioimpedance analysis). In addition, certain biochemical tests may be employed (e.g. 
albumin, pre-albumin). The various subjective-based and objective methodologies provide different 
insights for the assessment of PEW, particularly regarding their propensity to differentiate between the 
important body composition compartments – fluid overload, fat mass and muscle mass.
This review of currently available methods showed that no single approach and no single marker is 
able to detect alterations in nutrition status in a timely fashion and to follow such changes over time. 
The most clinically relevant approach presently appears to be the combination of the SGA method 
with the bioimpedance spectroscopy technique with physiological model and, additionally, laboratory 
tests for the detection of micro-nutrient deficiency.
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Introduction
Multiple metabolic and nutritional derangements are present in 20–50% of patients 
with advanced chronic kidney disease (CKD)1. A variety of terms have been coined 
to describe this condition, such as uremic malnutrition2, uremic cachexia3, protein 
energy malnutrition4, malnutrition-inflammation atherosclerosis syndrome5 or 
malnutrition-inflammation complex syndrome6. More recently, the term “malnutrition” 
has been replaced by “wasting” in recognition that the disorder cannot be corrected 
by simply increasing dietary nutritional intake. In fact, the deterioration of kidney 
function is often associated with inflammation, metabolic acidosis, and impaired 
insulin/insulin-like growth factor functionality, all of which negatively affect protein 
anabolism even in presence of an adequate nutritional intake. As a consequence, 
the International Society of Renal Nutrition and Metabolism defined protein-energy-
wasting (PEW) according to the presence of at least three out of the following four
characteristics7: (1) Abnormal levels of circulating biomarkers (low serum albumin, 
pre-albumin, or cholesterol concentrations); (2) Decreased body mass (low or 
decreased body mass or fat mass, or weight loss with decreased protein and energy 
intake); (3) Decreased muscle mass; and (4) Abnormal nutritional score. However, 
even severely reduced muscle mass can be masked by a parallel increase in non-
muscle body weight (even to overweight and obese levels), making a diagnosis of 
PEW difficult in such cases. 
While the nutritional and metabolic derangements observed in advanced CKD 
cannot be attributed to any one single factor, a common feature is the high rate of 
protein degradation. Chronic inflammation can be a cause of PEW in CKD
patients8,9. Chronic inflammation is not only associated with advanced kidney 
disease itself, but also with the biological response to the dialysis treatment 
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(including catheters) and with the presence of comorbid conditions, such as diabetes 
mellitus, tumors or infections. Another factor that plays a role is the inadequate 
intake of nutrients, for example due to loss of appetite, dietary restrictions, pill-
burden, lack of physical activity, the disruptive influence of dialysis scheduling on 
meal times, and failure to compensate for nutrient losses (e.g. in the dialysate). 
Lastly, intercurrent events leading to frequent hospitalizations of dialysis patients 
have been associated with worsening of the patient’s nutrition status10. 
When PEW is present, patient mortality risk and hospitalization rate increase 
dramatically11. In order to hinder, or at least delay, the development of PEW in 
dialysis patients, the European Best Practice Guidelines recommend a close follow 
up of patient nutrition status from the initiation of renal replacement therapy12.
This article aims to provide an overview of the different nutritional markers and the 
available methodologies for the physical assessment of nutrition status, with special 
emphasis on early detection of PEW.
Available methods for evaluating the nutrition status of hemodialysis patients
Nutrition status assessment relies on anamnesis, physical examination, evaluation of 
nutrient intake, and on a selection of various screening/diagnostic methodologies. 
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The last can be subjective in character (such as the Subjective Global Assessment 
score, see Table 1) or objective in nature (for example, employing anthropometric 
indices, body composition tools or functionality tests, see Table 2).
In addition, certain biochemical tests may be employed, for example measurements 
of serum albumin, pre-albumin, creatinine index, and protein catabolic rate. Table 3
provides an overview of which PEW relevant factors are included in the different 
scoring tests commonly used today.
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The ability to objectively identify reduced muscle mass is clearly critical for the 
diagnosis of PEW. Today, several methodologies are available targeting detection of 
changes in body composition and especially reductions in muscle mass (Table 2). 
These include  anthropometric approaches, evaluation of creatinine generation13, 
dual-energy X-ray absorptiometry14 bioimpedance-based evaluations of body 
composition14,15, and other methodologies less likely to be used in routine clinical 
practice (e.g. nuclear magnetic resonance, computerized tomography, total body 
nitrogen, and total body potassium)16. In addition, an indirect assessment of muscle 
mass can be performed via muscle strength, i.e. by using hand-grip test, or via 
subjective evaluation of the daily routine activities, as reported in specific questions 
of the SF-36 questionnaire17.
Special requirements for early identification of PEW
A main target of nutrition status assessment is the detection of early warning 
indicators for PEW, especially as such may offer opportunities for timely 
interventions with the potential to stop ongoing cachectic processes. For the 
assessment of nutrition status it is essential to perform a precise and specific 
compartment evaluation, identifying fat mass, muscle mass and potential fluid 
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overload separately.  This compartmental approach is important as the therapeutic 
approaches to addressing impairments can be very different from compartment to 
compartment. For example, CKD patients can accumulate significant amounts of fat 
mass18, but at the same time suffer from depletion in the muscle mass19,20, e.g. in 
protein energy malnutrition. Therefore, it is essential to assess fat and muscle mass 
independently. It is equally necessary to assess fluid overload independent from 
muscle mass and adipose mass: muscle is 72% water21 and for every 1 kg of muscle 
mass a patient catabolizes 720 ml of fluid will be released. In the case of a patient 
with CKD 5, this fluid will accumulate in the body. The weight of the patient will 
decrease slightly, but at the same time muscle mass is replaced by fluid volume. 
Various technical methods exist that can assess the different composition properties 
of the human body. Table 4 compares the different objective methods regarding their 
propensity for differentiation between the different body composition compartments –
fluid overload, fat mass and muscle mass. 
Which methods provide the best information?
Methods for nutrition assessment are applied as diagnostic, prognostic and/or 
response-tracking tools. Which method is most suitable for which application is a 
matter of controversy since malnutrition is a continuum triggered by an imbalance 
between intake and requirements for energy, protein and other nutrients. In addition, 
these requirements also depend on the actual health status of the individual (i.e. 
healthy vs. chronically ill). Another important question to address is what exactly the 
different methods assess, and if they are actually capable of timely identification of 
PEW. Here it is important to separate between tools that are used for screening (like 
SGA) and methods that can be used for long-term follow-up of a patient (e.g. 
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bioimpedance spectroscopy based on physiological models). Consequently, different 
methods can be used in different stages of malnutrition, taking into consideration that 
detectable alterations in body composition occur rather late in the development of 
PEW.
The first fundamental classification of methods used to assess nutritional status 
categorizes these as being either subjective or objective in character. Table 3
provides an overview of the different malnutrition parameters tested by six 
recognized partially subjective methods. The subjective Global Assessment (SGA), 
the Malnutrition Inflammation Score (MIS) and the Mini Nutritional Assessment Short 
Form (MNA-SF) score cover a wider range of parameters than the Nutritional Risk 
Score (NRS), the Malnutrition Universal Screening Tool (MUST) and the Geriatric 
Nutritional Risk Index (GNRI).  The SGA score is globally recognized as a validated 
tool for the cross-sectional assessment/screening for risk of PEW and also facilitates 
comparison of different populations22. In terms of nutritional dimensions, the SGA 
score offers the highest coverage. On the negative side, it requires clinical expertise 
for reliable application and is not sufficiently sensitive for longitudinal patient follow 
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up, as subtle changes in nutrition status would not be detectable23. GNRI is the most 
restrictive method, assessing only weight loss and laboratory values. These tests are 
not set up to reflect the special conditions of CKD patients.   In addition to the 
methods listed in Table 3, many other partially subjective tests exist, but the decision 
to use a particular tool has to be considered carefully since many of them have not 
been validated24.
Objective methods with high clinical applicability are essential for the diagnosis of 
PEW. As previously mentioned, a reliable diagnosis requires differentiation between 
the three main body composition compartments: fat mass, lean mass and fluid 
overload. Table 4 provides an overview of the ability of different objective methods to 
make such a differentiation. The advantages of the various methods depend on the 
exact kind of information they can provide, their ease of use, their respective costs 
and the respective clinical applicability. 
From the anthropometric methods, neither weight, nor BMI nor mid-arm 
circumferences are able to differentiate between the different compartments (muscle 
mass, fat mass and fluid overload). Furthermore, the results can be affected by 
deviations in fluid balance in patients with CKD25. Consequently, large muscle mass 
and large fat mass will be interpreted in the same way when using these methods. 
Body fat accumulates to around 33% in subcutaneous tissue, to about 10% in 
intramuscular depots of males (4% in females), and to around 12% in visceral 
thoracic and abdominal fat depots in males (8% in females). Subcutaneous fat can 
be assessed by precision calipers, measuring the skin fold thickness. With skin fold 
thickness it is possible to get quite a good approximation for the fat mass but the 
results are highly clinician and device dependent, do not assess muscle mass and 
are affected by fluid overload and edema25. Consequently, the accuracy of the 
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results is quite low, even more so in obese people. Experienced clinicians usually 
need to make three consecutive measurements and average the results. In addition, 
skin fold thickness represents the subcutaneous fat that differs by location in the 
body with a distribution that is gender specific25. Waist-hip ratio gives a good 
indicator for the amount of visceral fat, and is therefore a better marker for obesity 
and for the fat mass than weight or the BMI. However, in general, anthropometric 
measures are considered vulnerable to errors and are not recommended for 
diagnosing sarcopenia26. Finally, according to Vagianos et al27, one should consider 
that subjects who appear well-nourished according to anthropometric measures can 
actually be malnourished because of a deficiency in multiple micronutrients (e.g. 
iron, vitamin B6, vitamin D). This was shown in a study of patients with inflammatory 
bowel disease, but cannot be ruled out in CKD patients. 
The value of functional methodology for nutritional or PEW assessment is still under 
discussion. Muscle strength has been shown to be positively associated with muscle 
mass and, possibly, negatively associated with inflammation28,29. However, a recent 
systematic review30 concluded that the protocol for hand-grip test is not standardized 
and that diagnostic criteria are still missing. Nevertheless, functional tests are 
generally considered a reliable indicator of short-term changes in nutrition status and 
surrogate of physical activity31.
Dual X-ray absorptiometry (DEXA) provides precise assessment of the fat mass and 
is sometimes regarded as the “gold standard” for the fat mass assessment32.  DEXA 
was able to detect  significant increases in fat mass and significant decreases in lean 
body mass during the first year on hemodialysis treatment33. Pitfalls of this method 
are its complexity and cost, thereby limiting its clinical practicability, especially in the 
measurement of obese patients. In addition, this method cannot provide diagnostic 
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separation of muscle mass and fluid overload. The best method for assessing fat 
mass in patients with an impaired fluid status is the four-compartment model, which 
takes into account the bone mineral mass measured with DEXA, the total water 
content of the body assessed with Deuterium dilution, the weight of the patients, and 
the density assessed with air displacement plethysmography34. This method can be 
regarded as a further development of the DEXA assessment of fat mass in patients 
with an impaired renal function, but is very complex in its application. 
Bioimpedance analysis (BIA) methods, on the other hand, are comparatively 
inexpensive and easily applicable. In addition, they can be repeated frequently due 
to their non-invasive nature, i.e. patients are not exposed to additional health risks 
such as radiation. There are several different types of bioimpedance methods 
available today, and the results may vary depending on which type is applied. The 
simple mono-frequency or multifrequency bioimpedance analysis (BIA) methods are 
limited in their validity for CKD patients. This is especially because the empirical 
equations used here to convert measured impedances into clinically meaningful 
information were developed for healthy subjects, and the results cannot be 
extrapolated to a CKD population with markedly impaired hydration status. As a 
consequence, simple mono-frequency or multifrequency BIA cannot distinguish 
muscle mass from the fluid overload. However, by measuring the phase angle (i.e. 
the angular transformation of the ratio between reactance and resistance), one can 
anticipate the change in biochemical nutritional parameters35. Accordingly, by using 
single frequency BIA it was possible to unveil the risk of malnutrition also in 
apparently healthy overweight and obese patients on hemodialysis36, including also 
those on the waiting list for kidney transplantation37. The Bioimpedance Vector 
Analysis (BIVA) is a more advanced methodology. However, this also does not 
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provide absolute values of the various body composition compartments, and the 
results are always relative to the respective healthy reference population.  It also 
cannot separate fat and fluid compartments. Bioimpedance spectroscopy without a
physiological model provides a precise assessment of the extracellular and total 
body water. The extra- and intracellular compartments are distinguished already on 
measurement by using a frequency sweep from 3-5 kHz up to 1000 kHz. The body 
composition (fat free mass and fat mass) is then calculated using empirical 
equations and the resistance and reactance values of the 50 kHz frequency 
measurement38. These equations are identical to the equations used in the mono 
and multifrequency bioimpedance methods and are not valid in CKD patients. 
Furthermore, the important fluid overload compartment cannot be determined.
The Bioimpedance Spectroscopy method with physiological model is the only 
method available today that is able to distinguish between the 3 different body 
compartments. The well-validated physiological model39 facilitates separation of the 
body into the three essential compartments, lean body mass, adipose tissue mass, 
and fluid overload. Therefore, the Bioimpedance Spectroscopy method with 
physiological model is the only clinically practical method that allows the diagnostic 
separation necessary for the diagnosis of PEW. Ratios of intracellular water or 
extracellular water to body weight, assessed with bioimpedance spectroscopy were 
found to be good markers of nutrition status in a Portuguese study of 75 HD 
patients40. Using the same method, Rosenberger et al41 recently showed that  lean 
tissue index levels in hemodialysis patients below the 10th percentile of an age and 
gender matched distribution in the normal population are associated with a 
significant 66% higher relative risk for mortality. Applying the same type of BIA, 
Broers et al42 were able to detect a seasonal pattern to body composition and 
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hydration state, thereby potentially facilitating longitudinal evaluation of nutritional 
status.     
The additional value of laboratory tests
Despite our focus on physical measurements for nutritional assessment, laboratory 
measurements relevant to nutritional assessment should also be mentioned here. 
These are mainly albumin, pre-albumin, creatinine index and protein catabolic rate. 
Micro-nutrients are sometimes also measured in CKD patient laboratory tests (e.g. 
serum iron, vitamin D), but will not be discussed here. Serum albumin is not only a 
marker of visceral proteins, but also of overhydration and inflammation43,44. 
Therefore it is not the best indicator to assess nutrition status and, according to 
Fuhrman45, may be a more appropriate indicator for disease severity. Pre-albumin 
(transthyretin) is believed to be a better nutritional indicator than albumin, with higher 
sensitivity because of its shorter half-life (2.5 days)46. However, this may have 
limitations similar to albumin, and is not a standard laboratory parameter that is 
checked in CKD and dialysis patients. In patients with healthy metabolic status, 
creatinine generation is an indicator of muscle mass. In CKD patients, serum 
creatinine reflects muscle mass but is affected by renal function. For patients on 
dialysis, serum levels then also depend on dialysis dose (Kt/V) due to the small 
molecular weight and removal of creatinine during treatment. Canaud et al13
developed a simplified formula to derive creatinine generation in dialysis patients 
from a combination of serum creatinine levels, Kt/V and anthropometric measures. 
However, this inexpensive indicator, even if potentially useful for monitoring the lean 
body mass of patients on dialysis, has its limitations in the high prevalence of 
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protein-energy wasting, the interference of dietary meat intake and the associated 
catabolic status. Finally, protein catabolic rate (nPCR) is considered a surrogate 
marker for dietary protein intake. In stable CKD patients this is estimated from the 
nitrogen balance (24-hour urine collection), whereas in patients on hemodialysis it is 
mainly derived from Kt/V. Again, it can be considered a reliable nutritional indicator 
only under stable metabolic conditions.
Summary
This review of currently available methods to assess nutrition status showed that no 
single approach and no single marker is able to detect alterations in nutrition status 
in a timely fashion and to follow such changes over time. This is especially the case 
for patients with CKD and for patients on dialysis where issues of fluid overload may 
affect the results. Overall, the ideal nutrition assessment tool has to be specific, 
reliable, inexpensive, non-invasive and easy to use. Considering the intrinsic 
limitations of all nutritional markers, we support the multi-perspective approach with
a combination of measures and a stepwise procedure: 
1. A subjective clinical assessment, relying on validated SGA for screening and early 
detection of malnutrition; and 
2. An assessment of the body composition by bioimpedance spectroscopy with the 
physiological model for quantifying and ensuring follow up of patients at risk of 
malnutrition, or patients with already established PEW, also in order to verify medium 
to long term improvement after the initiation of a nutritional therapy. 
3. Use of available laboratory parameters, such as albumin or CRP for inflammation.
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Special focus should be placed on patients at higher risk of PEW, such as diabetics, 
patients after failed kidney transplantation, and patients transferred from previous 
peritoneal dialysis treatment. A major advantage of bioimpedance spectroscopy with 
physiological model in CKD patients is the fact that it is the only method that is able 
to detect fluid overload. This method should be used on a routine basis not only in all 
CKD 5 but also already in the CKD 3 and 4 stages.  Hand-grip tests may be very 
useful for early detection and even for short-term evaluation of a corrective therapy, 
but the current lack of standardization remains problematic.
In summary, the most clinically relevant approach to assessing nutrition status in 
hemodialysis patients presently appears to be the combination of the SGA method 
with the bioimpedance spectroscopy technique with physiological model and, 
additionally, laboratory tests for the detection of micro-nutrient deficiency, specifically 
in a very early phase of malnutrition.
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Abstract
Objective
In patients with advanced kidney disease, metabolic and nutritional derangements induced by uremia 
interact and reinforce each other in a deleterious vicious circle. Literature addressing the effect of 
dialysis initiation on changes in body composition (BC) is limited and contradictory.  Aim of this study 
was to evaluate changes in BC in a large international cohort of incident hemodialysis patients. 
Methods
8227 incident adult ESRD patients with BC evaluation within the initial first 6 months of baseline,
defined as 6 months after RRT initiation, were considered. Body composition, including fat tissue 
index (FTI) and lean tissue index (LTI), were evaluated by Body Composition Monitor® (BCM, 
Fresenius Medical Care, Bad Homburg, Germany). Exclusion criteria at baseline were lack of a BCM 
measurement before or after baseline, BMI <18.5 kg/m2, presence of metastatic solid tumors, 
treatment with a catheter, and prescription of less or more than 3 treatments per week. Maximum 
follow-up was 2 years. Descriptive analysis was performed comparing current values with the baseline 
in each time interval (delta analysis). Linear mixed models considering the correlation structure of the 
repeated measurements were used to evaluate factors associated with different trends in FTI and LTI. 
Results
BMI increased about 0.6 kg/m2 over 24 months from baseline. This was associated with increase in 
FTI of about 0.95 kg/m2 and a decrease in LTI of about 0.4 kg/m2. Female gender, diabetic status and 
low baseline FTI were associated with a significant greater increase of FTI. Age >67 years, diabetes, 
male gender, high baseline LTI and low baseline FTI were associated with a significantly greater 
decrease of LTI.
Conclusions
With the transition to hemodialysis, ESRD patients presented with distinctive changes in BC. These 
were mainly associated with gender, older age, presence of diabetes, low baseline FTI and high 
baseline LTI. BMI increases did not fully represent the changes in body composition.
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Introduction
The prevalence of protein-energy wasting is very high in dialysis patients1 because 
of the synergic contribution of decreased protein and/or energy intake, chronic 
inflammation, physical inactivity, concurrent acute or chronic conditions or illness, 
and catabolism induced by hemodialysis process.2 On the basis of the repetitive and 
prolonged nature of these processes, a deterioration of the nutritional status should 
be concurrent, and longitudinal studies should capture their close association.
However, the initiation of hemodialysis might also improve nutritional state, e.g.  by 
improving appetite due to the partial reversal of the uremic state and correction of 
metabolic acidosis. Pupim et al3 in 2002 showed that the initiation of hemodialysis 
was associated with significant improvement of most nutritional markers, including 
albumin, prealbumin, dietary protein intake derived from nitrogen appearance rate 
(nPCR), and body composition such as fat mass (1.29±2.20 kg). Vendrely et al4, in a 
study evaluating the fat and lean body mass development during the first year on 
hemodialysis in 15 patients previously treated with supplemented very low protein 
diet and 15 patients on less restricted diet, found a significant increase in fat mass 
(12.6±18.7% and 16.6±16.1%, respectively). Lean mass remained stable overall in 
the two groups of patients. On the other hand, other studies showed that lean body 
mass significantly decreased after 24 months.3, 5 The increase in albumin and 
creatinine levels during the first 6 months of hemodialysis also reported by 
Goldwasser et al6 can be explained by the decline of renal function and the 
progressive retention of proteins and creatinine. A study by Raffaitin et al7 on a 
group of 10 diabetic patients starting dialysis and monitored by means of DXA 
confirmed a significant decrease in lean tissue mass and serum albumin over a 
period of two years.
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A more recent study from Mathew et al8, evaluating 41 prevalent hemodialysis or 
peritoneal dialysis patients surviving 24 months after their baseline anthropometric 
evaluation, showed a significant increase in triceps and biceps skin fold thicknesses 
and mid-arm circumference. Finally, Kalantar–Zadeh et al 9 evaluated the body fat in 
535 prevalent hemodialysis patients by near infrared interactance. After 6 months 
they found that the 411 patients still on follow-up were stratified as follows: 27.5% 
with significant fat loss and 29.9% with significant fat gain. Similarly, Johansen et 
al10, evaluating 54 prevalent hemodialysis patients with 4 measurements of fat mass 
and lean mass by DEXA over a year, did not find any significant trend.
In summary, the number of studies evaluating changes in nutritional parameters after 
the initiation of dialysis is limited and largely based on longitudinal studies in 
prevalent patients, often with contradictory results. This observational study in a 
large cohort of incident hemodialysis patients regularly monitored with bioimpedance 
spectroscopy aims to assess changes in body composition in the initial phase of 
renal replacement therapy.
Methods
The study population was extracted from a database of 49,846 patients on 
hemodialysis treatment in 417 NephroCare centres throughout 21 countries in 
Europe, Latin America and South Africa between January 1, 2007 and January 1, 
2014.  Patients were included if they were no longer than 6 months on RRT before 
admission to the unit (incident patients only) and if they underwent evaluation of 
body composition using the Body Composition Monitor (BCM®, Fresenius Medical 
Care, Germany). Baseline was defined as six months after hemodialysis initiation. 
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Baseline values were defined as the mean of all measurements in the last 5 months 
before baseline (baseline period, Figure 1). Patients were followed for a maximum of 
2 years. Patients without at least one BCM-measurement before and after baseline 
(defined as 6 months after RRT initiation) were excluded. In order to focus on a 
homogenous well-treated hemodialysis population and to avoid including patients 
already having a poor outcome at study start, patients were also excluded who were 
malnourished (BMI < 18.5 kg/m2), had metastatic solid tumors, were receiving less or 
more than 3 treatments per week, or were treated with a catheter at baseline.
Anonymized patient data were accessed through the European Clinical Database 
(EuCliD), which has been described elsewhere.11, 12  All patients consented that their 
data may be used for scientific research in anonymized form.
Lean Tissue Index (LTI) and Fat Tissue Index (FTI) were calculated as the ratio of 
the respective tissue masses divided by the height in meters squared. The definition 
of the age- and gender-dependent reference groups of LTI and FTI, respectively, 
was based on an evaluation of 1000 healthy individuals: “normal” LTI and FTI were 
defined as levels between the 10th and 90th percentile of the normal LTI or FTI 
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distribution, respectively, whereas “low“ is defined as under the 10th percentile and 
“high” as above the 90th percentile of the respective normal distributions.13
Lean tissue index and fat tissue index were evaluated at intervals defined according 
to the network policy using the BCM® (FMC, Bad Homburg, Germany), which is 
based on multifrequency bioimpedance spectroscopy at 50 different frequencies 
ranging between 5 and 1000 kHz. BCM® measures overhydration, total body water 
(TBW in L), extracellular water (ECW in L), intracellular water (ICW in L), fat tissue 
mass (FTM in Kg), lean tissue mass (LTM in Kg) and body cell mass. BCM has been 
validated against the following gold standard reference methods: bromide dilution for 
ECW, total body potassium for ICW, deuterium dilution for TBW, dual X-ray 
absorptiometry for LTM, four compartment modelling, air displacement 
plethysmography, under water weighing for adipose tissue mass, magnet resonance 
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tomography for body cell mass and an expert clinical assessment for 
overhydration.14
Statistical analysis
The outcomes body mass index (BMI), lean tissue index (LTI) and fat tissue index 
(FTI) were analysed to evaluate the nutrition status of the patients. Descriptive 
analysis was performed comparing current values for each patient with their baseline 
values for each 1-month interval (Delta-analysis). In cases without a measurement in 
the interval, the value of the previous interval was used (last observation carried 
forward). 
To analyse differences between certain patient groups in the development of BMI, 
LTI and FTI, linear mixed models were used. We applied an autoregressive process 
of first order as covariance structure to consider the specific structure of the repeated 
measurements in irregular time intervals. For each outcome (BMI, LTI and FTI) a 
separate mixed model with an adjustment for the three cardiovascular comorbidities 
chronic ischemic heart disease (ICD10 code I25), heart failure (ICD10 code I50) and 
peripheral arterial diseases (PAD) (ICD 10 codes I70-I79) were fitted. In each model 
the time (in days) was included as covariate. In addition, the factors gender, age (in 
tertiles: 18-56; 57-66; ≥67), diabetes, LTI- and FTI-reference groups (“Low”, 
“Normal”, “High”) were included as main effects and as interactions with time. The 
main effects show average differences in the body composition between certain 
subgroups. Interaction terms between the factors and the time are used to identify if 
the changes in BMI, FTI and LTI differ in these subgroups over time during the 2 
years of follow-up.
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All covariates were categorical and therefore were included in the model as dummy-
variables. The corresponding reference categories are reported in the tables in the 
Results section. Because of the high number of covariates, Akaike information 
criterion (AIC) was used to select covariates. AIC model selection balances between 
the goodness of fit and the complexity of the model and can therefore result in 
exclusion of some covariates that have a low impact on the outcome. The analysis 
was conducted with the statistical software SAS, version 9.4.
Results
Patient selection is shown in Figure 2. After the selection process 8227 patients out 
of the original 49,846 patients were recruited. Baseline characteristics are displayed 
in Table 1. During the baseline period patients had a median of 4 (interquartile range 
(IQR): 2-5) BCM measurements. On average, patients had a median of 7 (IQR: 3-14) 
BCM measurements after baseline, the last of which was in mean 319 days after 
baseline. Figure 3 shows the means of the delta analyses. In two years of follow-up, 
the BMI increased by ~0.6 kg/m2 (or 2.2%). This change was mainly the result of an 
increase of 0.95 kg/m2 (7.4%) in FTI and a decrease of 0.4 kg/m2 (3.1%) in LTI. 
These changes in BMI, FTI and LTI were significant for all intervals (p<0.001, paired 
t-tests).
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The results of the linear mixed models for the outcomes BMI, FTI and LTI are shown 
in Tables 2-4. All covariates are listed with the appropriate reference categories and 
the estimations for the specified groups, the standard errors and the p-values. The 
results for the time-interactions are highlighted in the following, these being most 
relevant to the study aim.
Results for BMI:
After AIC selection the model for BMI no longer contained periphery artery disease, 
heart failure and the interaction term of diabetes and time (Table 2). Diabetes did not 
significantly affect the development of BMI. BMI increased more for females than for 
males, more for patients <57 years than for patients ≥67 years, and more for patients 
with normal LTI and normal FTI than for patients with high LTI and FTI at baseline. 
The model results can also be summarized as follows:
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ܤܯܫሺݐ݅݉݁ሻ ൌ ʹͷǤ͹ͺ ൅ ͲǤͲͲʹͺ כ ݐ݅݉݁ ൅ ൜െͲǤʹ͹ െ ͲǤͲͲͳ כ ݐ݅݉݁݈݉ܽ݁Ͳ݂݈݁݉ܽ݁
൅ ቐ
ͲǤʹʹ െ ͲǤͲͲͲͻ כ ݐ݅݉݁ ൒ ͸͹ݕ݁ܽݎݏ
ͳǤͲʹ െ ͲǤͲͲͲͶ כ ݐ݅݉݁ሾͷ͹Ǣ ͸͹ሻݕ݁ܽݎݏ
Ͳ ൏ ͷ͹ݕ݁ܽݎݏ
൅ ቄͲǤͺ͸ܾ݀݅ܽ݁ݐ݁ݏͲ݊݋ܾ݀݅ܽ݁ݐ݁ݏ
൅ ቄͲǤ͵ͷ݅ݏ݄ܿ݁݉݅ܿ݄݁ܽݎݐ݀݅ݏ݁ܽݏ݁Ͳ݊݋݅ݏ݄ܿ݁݉݅ܿ݄݁ܽݎݐ݀݅ݏ݁ܽݏ݁ ൅ ൝
െʹǤͲ͸ ൅ ͲǤͲͲͲʹ כ ݐ݅݉݁݈݋ݓܮܶܫ
ʹǤ͹͸ െ ͲǤͲͲͳͷ כ ݐ݅݉݁݄݄݅݃ܮܶܫ
Ͳ݊݋ݎ݈݉ܽܮܶܫ
൅ ൝
െͶǤͻ͹ ൅ ͲǤͲͲͲͷ כ ݐ݅݉݁݈݋ݓܨܶܫ
ͺǤ͸ͻ െ ͲǤͲͲͳͷ כ ݐ݅݉݁݄݄݅݃ܨܶܫ
Ͳ݊݋ݎ݈݉ܽܨܶܫ
Example: female, between 57 and 66 years old, no diabetes, no ischemic heart 
disease, with low LTI and high FTI:
ܤܯܫሺݐ݅݉݁ሻ ൌ ʹͷǤ͹ͺ ൅ ͲǤͲͲʹͺ כ ݐ݅݉݁ ൅ ͳǤͲʹ െ ͲǤͲͲͲͶ כ ݐ݅݉݁ െ ʹǤͲ͸ ൅ ͲǤͲͲͲʹ כ ݐ݅݉݁
൅ ͺǤ͸ͻ െ ͲǤͲͲͳͷ כ ݐ݅݉݁ ൌ ͵͵ǤͶ͵ ൅ ͲǤͲͲͳͳ כ ݐ݅݉݁
After 2 years of follow-up: ܤܯܫሺ͹͵Ͳሻ ൌ ͵͵ǤͶ͵ ൅ ͲǤͲͲͳͳ כ ͹͵Ͳ ൌ ͵ͶǤʹ͵
Results for FTI:
After AIC selection heart failure and the interaction term between age and time were 
no longer in the model. In this model age did not appear to affect FTI development 
as the interaction term between age and time was not significant (Table 3). FTI 
increased more for females than for males, more for diabetics than for non-diabetics, 
more for patients with normal versus low baseline LTI, and more for patients with low 
baseline FTI. The increase of FTI over the time was smallest for patients with high 
FTI at baseline. The corresponding formula is:
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ܨܶܫሺݐ݅݉݁ሻ ൌ ͳͳǤͷ͵ ൅ ͲǤͲͲ͵ כ ݐ݅݉݁ ൅ ൜െ͵Ǥʹͻ െ ͲǤͲͲͳ כ ݐ݅݉݁݈݉ܽ݁Ͳ݂݈݁݉ܽ݁
൅ ቐ
ʹǤͶͶ ൒ ͸͹ݕ݁ܽݎݏ
ͳǤͻͻሾͷ͹Ǣ ͸͹ሻݕ݁ܽݎݏ
Ͳ ൏ ͷ͹ݕ݁ܽݎݏ
൅ ቄͲǤ͹ʹ ൅ ͲǤͲͲͲͻ כ ݐ݅݉݁ܾ݀݅ܽ݁ݐ݁ݏͲ݊݋ܾ݀݅ܽ݁ݐ݁ݏ
൅ ቄͲǤʹͷ݅ݏ݄ܿ݁݉݅ܿ݄݁ܽݎݐ݀݅ݏ݁ܽݏ݁Ͳ݊݋݅ݏ݄ܿ݁݉݅ܿ݄݁ܽݎݐ݀݅ݏ݁ܽݏ݁ ൅ ቄ
ͲǤͳͷܲܣܦ
Ͳ݊݋ܲܣܦ
൅ ൝
ͲǤͺͺ െ ͲǤͲͲͲ͸ כ ݐ݅݉݁݈݋ݓܮܶܫ
െͲǤͷͲ ൅ ͲǤͲͲͲͳ כ ݐ݅݉݁݄݄݅݃ܮܶܫ
Ͳ݊݋ݎ݈݉ܽܮܶܫ
൅ ൝
െͷǤͺͲ ൅ ͲǤͲͲͳ כ ݐ݅݉݁݈݋ݓܨܶܫ
ͻǤʹͶ െ ͲǤͲͲʹ כ ݐ݅݉݁݄݄݅݃ܨܶܫ
Ͳ݊݋ݎ݈݉ܽܨܶܫ
Example: female, between 57 and 66 years old, no diabetes, no ischemic heart 
disease, without PAD, with low LTI and high FTI:
ܨܶܫሺݐ݅݉݁ሻ ൌ ͳͳǤͷ͵ ൅ ͲǤͲͲ͵ כ ݐ݅݉݁ ൅ ͳǤͻͻ ൅ ͲǤͺͺ െ ͲǤͲͲͲ͸ כ ݐ݅݉݁ ൅ ͻǤʹͶ െ ͲǤͲͲʹ
כ ݐ݅݉݁ ൌ ʹͶǤ͵͸ ൅ ͲǤͲͲͳ͵ כ ݐ݅݉݁
After 2 years of follow-up: ܨܶܫሺ͹͵Ͳሻ ൌ ʹ͵ǤͷͶ ൅ ͲǤͲͲͲͶ כ ͹͵Ͳ ൌ ʹ͵Ǥͺ͵
Results for LTI:
The same covariates were considered for the outcome LTI. After AIC selection the 
model no longer contained chronic ischemic heart disease (Table 4). LTI decreased 
more for males than for females, more for patients ≥67 years than patients <57 
years, more for diabetics, and more for patients with high LTI or low FTI at baseline. 
The smallest decrease in LTZ was observed for patients with low LTI or high FTI at 
baseline. The model results can also be summarized as follows:
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ܮܶܫሺݐ݅݉݁ሻ ൌ ͳ͵Ǥͻͳ െ ͲǤͲͲͲʹ כ ݐ݅݉݁ ൅ ൜ʹǤͺ͵ െ ͲǤͲͲͲʹ כ ݐ݅݉݁݈݉ܽ݁Ͳ݂݈݁݉ܽ݁
൅ ቐ
െʹǤ͸ͻ െ ͲǤͲͲͲ͵ כ ݐ݅݉݁ ൒ ͸͹ݕ݁ܽݎݏ
െͳǤʹʹ െ ͲǤͲͲͲʹ כ ݐ݅݉݁ሾͷ͹Ǣ ͸͹ሻݕ݁ܽݎݏ
Ͳ ൏ ͷ͹ݕ݁ܽݎݏ
൅ ቄെͲǤͳ͸ െ ͲǤͲͲͲ͹ כ ݐ݅݉݁ܾ݀݅ܽ݁ݐ݁ݏͲ݊݋ܾ݀݅ܽ݁ݐ݁ݏ ൅ ൜
െͲǤͳͳ݄݁ܽݎݐ݂݈ܽ݅ݑݎ݁
Ͳ݊݋݄݁ܽݎݐ݂݈ܽ݅ݑݎ݁
൅ ቄെͲǤʹͺܲܣܦͲ݊݋ܲܣܦ ൅ ൝
െʹǤͻͺ ൅ ͲǤͲͲͲͺ כ ݐ݅݉݁݈݋ݓܮܶܫ
͵Ǥͳͺ െ ͲǤͲͲͳͻ כ ݐ݅݉݁݄݄݅݃ܮܶܫ
Ͳ݊݋ݎ݈݉ܽܮܶܫ
൅ ൝
ͲǤ͸ͳ െ ͲǤͲͲͲ͸ כ ݐ݅݉݁݈݋ݓܨܶܫ
െͲǤ͵ʹ ൅ ͲǤͲͲͲ͵ כ ݐ݅݉݁݄݄݅݃ܨܶܫ
Ͳ݊݋ݎ݈݉ܽܨܶܫ
Example: female, between 57 and 66 years old, no diabetes, without heart failure, 
without PAD, with low LTI and high FTI:
ܮܶܫሺݐ݅݉݁ሻ ൌ ͳ͵Ǥͻͳ െ ͲǤͲͲͲʹ כ ݐ݅݉݁ െ ͳǤʹʹ െ ͲǤͲͲͲʹ כ ݐ݅݉݁ െ ͲǤͳͳ െ ʹǤͻͺ ൅ ͲǤͲͲͲͺ
כ ݐ݅݉݁ െ ͲǤ͵ʹ ൅ ͲǤͲͲͲ͵ כ ݐ݅݉݁ ൌ ͻǤʹͺ ൅ ͲǤͲͲͲ͹ כ ݐ݅݉݁
After 2 years of follow-up: ܮܶܫሺ͹͵Ͳሻ ൌ ͻǤʹͺ ൅ ͲǤͲͲͲ͹ כ ͹͵Ͳ ൌ ͻǤ͹ͻ
Discussion
This study, based on a large international cohort of incident hemodialysis patients, 
reports a mean BMI increase of ~0.6 kg/m2 over 24 months from baseline. Patient 
nutritional status was monitored by bioimpedance spectroscopy and revealed that 
changes in BMI were associated with an increase of 0.95 kg/m2 in FTI and a 
decrease of 0.40 kg/m2 in LTI. These latter results confirm trends reported by 
previous small-sized studies,3, 4, 7 albeit the increase in fat body mass reported by 
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Pupim et al3 during the first year on hemodialysis was not associated with significant 
changes in weight and in body mass index. This is the opposite of what was reported 
by Mathew et al8, but it should be stressed that anthropometry measurements are 
not only operator dependent but also subject to artifacts from fluid accumulation. 
Therefore, it cannot be excluded that previous results can be distorted by the
hydration status, especially considering that also DEXA cannot provide diagnostic 
separation of muscle mass and fluid overload. In the current study, the increase of 
fat and the decrease in lean body mass was associated with an increased BMI 
already after 1 year (Figure 3). This observation supports the theory3 that fat mass 
may increase quickly during the first year of hemodialysis and continue to increase 
slowly thereafter for approximately 7 years.
An additional analysis was conducted to analyze if changes in the nutritional 
parameters differ in different regions (West Europe (reference category), East 
Europe and Latin America & South Africa). Here, geographical area was included in 
the linear mixed models as main effect as well as interaction with the time. 
Significantly higher increases in BMI (0.0008 kg/m2 per day; p-value=0.002) and FTI 
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(0.0011 kg/m2 per day; p-value<0.001) were found for patients from East Europe 
compared to patients from West Europe. All other comparisons between the areas 
regarding the development of BMI, LTI and FTI were not significant.
Regarding the development of fat mass (Table 3), FTI increase was significantly 
lower for males compared to females, while the presence of diabetes was associated 
with a significantly higher increase of FTI over time. In agreement with the study of 
Pupim et al3, patients with the lowest baseline FTI showed the highest increase over 
time. In addition, patients with high baseline LTI showed the greater increase of fat 
tissue.
  
Regarding the loss of lean mass (Table 4), LTI decreased more in elderly patients 
(age ≥67 years) and males than in younger patients and females. It is known from 
previous studies assessing total body potassium in normal subjects that lean body 
mass peaks in the third and fourth decade of life, followed by a steady decline with
advancing age.15, 16 A more recent study17 in older adults based on 
hydrodensitometry evaluations showed a 2% decrease in fat-free mass per decade 
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in men but not in women, whereas fat mass increased similarly in both genders 
(7.5% per decade). It is known that the uremic state is associated with several 
endocrine abnormalities including the axis hypothalamus-pituitary gland-gonads 
regulation, growth hormone and insulin growth factor regulation, and hormone 
receptor interaction.18 The consequent hormonal derangement is known as uremic 
hypogonadism18, possibly affects the accelerated loss of muscle mass in men.17, 19
In our study diabetes was also significantly associated with a greater decrease in 
lean tissue index, confirming previous reports for older adults with type 2 diabetes 
not on renal replacement treatment.5, 20 Loss of lean tissue was higher in patients 
with lower baseline FTI and higher baseline LTI. One can speculate that if the energy 
reserve of fat is low, lean tissue (muscle mass essentially) catabolism is then 
facilitated. On the other hand, when the level of muscle mass is already low, the 
option to have further loss is quite limited.
Inflammation and metabolic acidosis cause wasting of muscle mass through a 
ubiquitin-mediated process.21 Patients treated with a catheter six months after 
initiation of renal replacement therapy were excluded from the study to ensure a 
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homogenous well-treated population, ruling out catheter as an inflammatory source. 
Recovery of visceral proteins (specifically albumin) after inflammatory events occurs 
fairly quickly, but regeneration of lost somatic proteins, specifically muscle, is less 
well assured. Although inflammation occurs in episodes in hemodialysis patients22, 
patients who have evidence of inflammation at one point in time are more likely to 
experience inflammation later. In an additional analysis we also considered the 
presence of a microinflammatory process by means of a C-reactive protein higher 
than 10 mg/dL, but we did not find any significant association, possibly due to the 
paucity of data points (data not shown). 
Non-CKD patients with other chronic diseases (e.g. breast cancer) frequently gain 
weight after diagnosis that is accompanied by either no change in lean tissue or with 
a loss of lean tissue. This pattern is defined as sarcopenic obesity and, like the 
pattern in dialysis patients, is associated with a long history of corticosteroid use, 
hypopituitarism, hypogonadism and prolonged physical inactivity.23, 24
This study has limitations inherent in any observation study, particularly that 
causality cannot be assumed. It is well known that physical exercise facilitates 
development of muscle and may blunt the negative impact of inflammation on 
muscle, but a surrogate, such as muscle strength, was not evaluated in this study. 
Also no direct comparison with a healthy population matched for age and gender 
was done. However, our previous study reported that as much as 47% of almost 
38,000 prevalent hemodialysis patients studied had LTI lower than the 10th percentile 
of an age and gender-matched healthy population.25 Diet changes may also affect 
the course of LTI and FTI changes, but the network does not prescribe diets nor 
were there adequate nPNA data available to facilitate investigation of this aspect. 
Another limitation was our assumption that the decrease in LTI was due to loss of 
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muscle mass. However, it is also possible that LTI loss may be affected by loss of 
bone, organ or connective tissue mass. Unfortunately, reliable data for residual renal 
function and for eGFR at time of initiation were not available. However, as baseline 
was defined at 6 months after initiation of renal replacement therapy, residual renal 
function can be assumed to be negligible. Strengths of the study lie in the 
prospective collection of data, the homogenous practice in all clinics, the reliability 
and frequency of body composition measurements, the large international cohort of 
incident patients and the statistical methodology applied versus previous studies. 
The level of homogeneity of hemodialysis practice in these clinics was high due to 
the clinics belonging to the same network and thus sharing a common set of medical 
and process targets, standard operating procedures and identical hemodialysis 
equipment/disposables. This was verified by a quality control tool that detects 
deviations and benchmarks outcome.26  
After admission to hemodialysis, patients generally experience an improvement in 
appetite and general well-being.27 This study reports an increase in weight in incident 
hemodialysis patients during two years of follow-up that is mainly the result of a 
significant increase in FTI. This was accompanied by a parallel, albeit of small 
magnitude, decrease in LTI. A recent retrospective study of 37,345 prevalent 
hemodialysis patients addressing the association between body composition and 
survival found mortality was lowest with both LTI and FTI in the 10th–90th percentile 
(reference group) and significantly higher at the lower LTI and FTI extreme.25
Interestingly, the results of our longitudinal study support the hypothesis generated in 
that cross-sectional study 25 of a possible protective effect of high FTI in patients with 
low LTI. Since malnutrition, LTI and FTI are recognized important predictors of 
outcome in hemodialysis patients, incident patients should be closely monitored from 
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the initiation of dialysis. Bio-impedance spectroscopy offers clinicians a convenient 
method to assess both fluid status and body composition changes. The findings of 
this study deserve further investigation including aspects of physical exercise and 
muscle strength to address body composition changes in incident dialysis patients in 
a more comprehensive manner. 
Practical Application
In the months after start of dialysis therapy, body mass index increased, fat tissue 
index increased, and lean tissue index decreased in this cohort of 8,227 incident 
hemodialysis patients. Some patient characteristics were associated with higher risk 
for having/developing malnutrition. The magnitude of the problem supports regular 
monitoring of all kidney disease patients in terms of body composition, at least from 
time of admission to dialysis.
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Abstract
Background
Dialysis patients are affected by protein energy wasting already early in renal replacement therapy. 
Serum albumin and creatinine levels are predictors of both nutritional status and of mortality risk in 
hemodialysis (HD) patients. We examined changes in these nutritional indicators in the 2 years 
following the first 3 months of HD.
Methods
The study population comprised HD patients treated in 27 countries between 2007 and 2014. Albumin 
and creatinine values in 1-month intervals were compared with their baseline values. Differences in 
the development between patient groups were analyzed using linear mixed models with the 
correlation structure of an autoregressive process of first order. 
Results
Of the 3860 patients, 295 died during follow-up. In one and two years of follow-up, albumin increased 
respectively by 4% and 4%, while creatinine increased by 12% and 18%. Compared to reference 
categories, albumin was significantly lower for females, older patients, patients with liver disease and 
patients with low lean tissue index (LTI) or low fat tissue index (FTI) at baseline. Creatinine was 
significantly higher for males, for patients with high LTI at baseline and for patients with malignancies, 
but was significantly lower for older patients, patients with congestive heart failure, peripheral vascular 
or cerebrovascular disease and diabetes, and patients with low LTI or low and high FTI at baseline. 
Regarding the development of over time, higher post-dialysis fluid overload at baseline was 
associated with a greater increase of both albumin and creatinine.
Conclusion
Serum albumin and creatinine levels improved in patients treated with a good dialysis protocol. The 
presence of post-dialysis fluid overload and certain comorbidities at baseline, such as vascular 
disease, liver disease and diabetes, can modify the positive trends.
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Introduction
Multiple metabolic and nutritional derangements negatively affect the nutritional 
status of patients with advanced chronic kidney disease (CKD) as their kidney 
function deteriorates. Additionally, starting renal replacement therapy has a major 
impact on patients’ nutritional status due to the following negative aspects: 
interference with regular meals, dietary restrictions imposed by clinician, loss of 
amino-acids and nutrients and dialysis-associated increased catabolic rate. These 
negative effects can only be partially counter-balanced by the increase in appetite 
and improvement in wellbeing resulting from uremia correction. Therefore, it is not 
surprising that many patients are affected by protein energy wasting (PEW) already 
in the initial phase of the renal replacement therapy. According to the International 
Society of Renal Nutrition and Metabolism1 this syndrome is defined by the presence 
of at least three of the following four characteristics: 1) abnormal levels of circulating 
biomarkers (low serum albumin, pre-albumin, or cholesterol concentrations); 2) 
decreased body mass (low or decreased body mass or fat mass, or weight loss with 
decreased protein and energy intake); 3) decreased muscle mass; and 4) abnormal 
nutritional score. Low serum albumin is an important biochemical indicator of PEW 
and it is part of the routine labs in the follow-up of dialysis patients. In addition, this 
visceral protein is an acute-phase protein, decreasing during inflammatory episodes, 
and accordingly is an important predictor of the risk of mortality as established by 
many studies2,3. Serum creatinine is also regularly monitored in many units, often 
once a month. It is dialyzable and in patients on maintenance hemodialysis its 
clearance is relatively constant across dialysis prescription. Creatinine generation is, 
however, proportional to dietary meat intake and mainly to somatic protein mass, 
with higher levels in those patients whose superior nutritional status sustains an 
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increased musculature. Finally, creatinine, similarly to albumin, has been found to be 
a strong predictor of mortality risk.4 Therefore, studies evaluating the development of 
the level of albumin and creatinine in the initial phase of dialysis should be 
considered in order to better use the information normally available from the routine 
continuous assessment. Strangely enough, few studies could be retrieved,4-11 and 
probably the recently published Comprehensive Dialysis study9 is the more 
exhaustive of these, showing an increased level of serum albumin in the initial 
months on dialysis. Another study from Goldwasser et al10 showed a 12-13%  
increase of serum albumin and creatinine during the first half year of hemodialysis in 
a stable cohort. The slope of serum albumin versus time predicted survival, but it 
was not as predictive as the absolute albumin concentration. In fact, the progressive 
decline in urinary excretion of proteins and creatinine was correlated with their 
increases in the serum levels. However, extracellular fluid overload may play an 
important role, being one of the factors affecting the concentration of albumin.
Therefore, having available a large population of incident patients admitted to 
hemodialysis, we sought to examine the changes in laboratory nutritional indicators 
such as albumin (visceral protein) and creatinine (somatic proteins) in the 2 years 
following the first 3 months of hemodialysis, in a phase when residual renal function 
is not expected to have major significant role.
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Subjects and Methods
The study population was extracted from a database of 69,316 patients on 
hemodialysis treatment in 605 NephroCare centres throughout 27 countries in 
Europe, Latin America and South Africa between January 1, 2007 and January 1, 
2014.  Patients were included if they were no longer than 3 months on RRT (incident 
patients only). Baseline values were defined as the mean of all measurements in the 
last 2 months before baseline (baseline period, Figure 1). Patients were followed for 
a maximum of 2 years after baseline. Patients with no albumin or with no creatinine 
measurement during the baseline period were excluded. Typically the bromocresol 
green method for albumin measurement was applied. In cases where the 
bromocresol purple method was used, results were converted to bromocresol green 
by adding 0.55 g/dL.12 Patients with no Lean Tissue Index (LTI) or with no Fat Tissue 
Index (FTI) measurement during this period were also excluded. LTI and FTI were 
calculated as the ratio of the respective tissue masses divided by the height in 
meters squared. The definition of the age- and gender-dependent reference groups 
of LTI and FTI, respectively, was based on an evaluation of 1000 healthy individuals: 
“normal” LTI and FTI is defined as levels between the 10th and 90th percentile of the 
normal LTI or FTI distribution, respectively, whereas “low“ is defined as under the 
10th percentile and “high” as above the 90th percentile of the respective normal 
distributions.13
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Figure 1. Study design with hypothetical measurement times. RRT: Renal replacement 
therapy
In order to ensure a homogenous, well-treated study population, patients younger 
than 18 years, with metastatic solid tumors, with a BMI lower 18.5 kg/m2, receiving 
less or more than 3 treatments per week, or  treated with a catheter at baseline were 
also excluded. Catheter patients were also excluded as it has been reported that 
central venous catheters are associated with a higher level of inflammation than 
fistula, as defined by C reactive proteins levels in incident hemodialysis patients14,15
with consequent significantly lower serum albumin concentration.9 Anonymized 
patient data were accessed through the European Clinical Database (EuCliD), which 
has been described elsewhere.16,17  All patients consented that their data may be 
used for scientific research in anonymized form.
Lean tissue index and fat tissue index were evaluated at intervals defined according 
to the network policy using the BCM® (FMC, Bad Homburg, Germany), which is 
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based on multifrequency bioimpedance spectroscopy at 50 different frequencies 
ranging between 5 and 1000 kHz. BCM® measures fluid overload, total body water 
(TBW in L), extracellular water (ECW in L), intracellular water (ICW in L), fat tissue 
mass (FTM in Kg), lean tissue mass (LTM in Kg) and body cell mass. BCM has been 
validated against the following gold standard reference methods: bromide dilution for 
ECW, total body potassium for ICW, deuterium dilution for TBW, dual X-ray 
absorptiometry for LTM, four compartment modelling, air displacement 
plethysmography, under water weighing for adipose tissue mass, magnet resonance 
tomography for body cell mass and an expert clinical assessment for fluid overload.18
Statistical analysis
Albumin and creatinine were analyzed during follow-up time to evaluate the changes 
in laboratory values after the start of dialysis. To describe the general changes of 
these two outcomes, a descriptive analysis was performed comparing current values 
with the baseline value in each 1-month interval (Delta-analysis). The mean delta 
and the standard error are plotted for each interval of the 2 years of follow-up 
thereafter. In case of an interval without measurement the value of the interval 
before was used (last observation carried forward). The Wilcoxon signed rank sum 
test was used to test the changes in albumin and creatinine in each month-interval 
compared to baseline. To consider the multiple comparisons, a Bonferoni correction 
was performed thereafter. P values less than 0.002 were considered to be significant 
in this case.
To analyze differences in the development of the laboratory values between certain 
patient groups, linear mixed models19 with the correlation structure of an 
autoregressive process of first order20 were used to consider the specific structure of 
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the repeated measurements in irregular time intervals.20 For both outcomes a 
separate mixed models were fitted. In each of them the time (in days) was included 
as covariate. Main predictors were gender, age (≥18 - <56; ≥56 - <69; ≥69) , LTI-
reference and FTI-reference groups (“Low”, “Normal”, “High”), post-dialysis fluid 
overload and the  comorbidities myocardial infarction,  congestive heart failure, 
vascular disease (peripheral vascular disease or cerebrovascular disease), diabetes 
with chronic complication, malignancy and liver disease (defined  according to the 
ICD10 coding algorithm,21 present (yes/no) at baseline). All these main predictors 
were included as main effect and as interaction with time. With the main effects 
general group differences could be analyzed. In addition the interaction terms are 
used to identify if the changes in albumin and creatinine over follow-up time differ in 
these subgroups.  
With the exception of the continuous variable fluid overload, all covariates are 
categorical and therefore were included in the model as dummy-variables. The 
corresponding reference categories are specified in detail in the tables. Because of 
the high number of covariates, Akaike information criterion (AIC) was used to select 
covariates. AIC model selection balances between the goodness of fit and the 
complexity of the model and can therefore result in exclusion of some covariates that 
have a low impact on the outcome. All analysis was conducted with the statistical 
software SAS, version 9.4. The SAS procedure MIXED together with the 
REPEATED statement and SPATIAL POWER correlation structure was used to fit 
the mixed models.
Results
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Patient selection is shown in Figure 2. After the selection process, 3860 patients out 
of the original 69,316 patients were included in the study. 97% of the selected 
patients were treated with arteriovenous fistula (3% grafts) and 97% with high-flux 
polysulfone dialyzers (Fresenius Medical Care, Germany).
Figure 2. Patient selection. RRT: Renal replacement therapy; LTI: Lean tissue index, FTI: 
Fat tissue index; BMI= Body mass index
295 patients (7.6%) died during follow-up. Baseline characteristics are displayed in 
Table 1.
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Table 1. Baseline patient characteristics
General characteristics
Age (years; mean±SD) 61.03±14.87
Age groups (%)
[18,56) years 
[56,69) years 
≥ 69 years
32.23
33.65
34.12
Gender (female, %) 35.75
Body composition
Post-dialysis weight (Kg; mean±SD) 72.73±14.90
BMI: body mass index (kg/m2; mean±SD) 26.74±5.18
LTI: lean tissue index (kg/m2; mean±SD) 13.06±2.94
LTI-reference groups (%)
Low LTI
Normal LTI
High LTI
45.10
51.79
3.11
FTI: fat tissue index (kg/m2; mean±SD) 12.70±6.16
FTI reference groups (%)
Low FTI
Normal FTI
High FTI
8.45
70.85
20.70
Pre-dialysis fluid overload (L; mean±SD) 2.16±1.96
Post-dialysis fluid overload (L; mean±SD) 0.16±2.13
Comorbidities
Myocardial Infarction (%) 3.32
Congestive heart failure (%) 10.31
Peripheral vascular disease (%) 7.20
Cerebrovascular disease (%) 7.07
Dementia (%) 0.47
Chronic pulmonary disease (%) 5.83
Rheumatic disease (%) 0.96
Peptic ulcer disease (%) 3.03
Diabetes with chronic complication (%) 28.37
Hemiplegia or paraplegia (%) 0.10
Malignancy (%) 5.36
AIDS/HIV (%) 0.05
Mild, moderate or severe liver disease (%) 4.84
Laboratory values
Albumin (g/dL; mean±SD) 3.77±0.44
Creatinine (mg/dL; mean±SD) 6.71±2.26
CRP ( mg/L; median; interquartile range) 5.66 [2.20-14.10]
Hemoglobin (g/dL; mean±SD) 10.37±1.47
Total cholesterol (mg/dL; mean±SD) 171.87±43.06
Phosphate (mg/dL; mean±SD) 4.82±1.33
Equilibrated Kt/V (mean±SD) 1.34±0.33
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During the baseline period patients had a median of 1 (interquartile range (IQR): 1-2) 
albumin and a median of 2 (IQR: 1-2) creatinine measurements. On average, 
patients had a median of 4 (IQR: 2-9) albumin and 6 (IQR: 2-13) creatinine 
measurements after baseline. The last albumin measurement was in mean 289, the 
last creatinine value 285 days after baseline. Figure 3 shows the means of the delta 
analyses. In one and two years of follow-up, albumin increased by 0.15 g/dL (or 4 %) 
and 0.14 g/dL (4 %), respectively. Creatinine increased by 0.8 g/dL (or 12 %) in one 
year and by 1.2 (18 %) in two years. These changes in albumin as well as in 
creatinine were significant for all intervals (p<0.001). The results of the linear mixed 
models for the outcomes albumin and creatinine after AIC variable selection are 
shown in Tables 2-3. All predictors are listed with the appropriate reference 
categories and the estimations for the specified groups, the standard errors and the 
p-values. 
Results for albumin:
Albumin is significantly higher for males then for females. In comparison to their 
reference categories, albumin is significant lower for patients older/equal than 56, 
patients with liver disease and patients with low LTI or low FTI at baseline. Higher 
post-dialysis fluid overload is also associated with lower albumin level at baseline, 
but regarding the development over the follow up time, higher post-dialysis fluid 
overload at baseline is associated with a greater increase of albumin. For patients 
without vascular disease, albumin increased more during follow-up time than for 
patients with this disease. The model results can also be summarized as follows:
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Albumin (time) = 3.92 + 0.00033 * time + ൜ͲǤͳͲ݈݉ܽ݁Ͳ݂݈݁݉ܽ݁ + ቐ
െͲǤʹͲ ൒ ͸ͻݕ݁ܽݎݏ
െͲǤͲͻሾͷ͸Ǣ ͸ͻሻݕ݁ܽݎݏ
Ͳ ൏ ͷ͸ݕ݁ܽݎݏ
+ ൝
െͲǤͲͻ݈݋ݓܮܶܫ
ͲǤͲͶ݄݄݅݃ܮܶܫ
Ͳ݊݋ݎ݈݉ܽܮܶܫ
+ ൝
െͲǤͳʹ݈݋ݓܨܶܫ
ͲǤͲͷ݄݄݅݃ܨܶܫ
Ͳ݊݋ݎ݈݉ܽܨܶܫ
+ 
൜ ͲǤͲͶ݉ݕ݋ܿܽݎ݈݀݅݊ܽ݂݅݊ܽݎܿݐ݅݋݊Ͳ݊݋݉ݕ݋ܿܽݎ݈݀݅݊ܽ݂݅݊ܽݎܿݐ݅݋݊
+ 
൜ ͲǤͲͳ െ ͲǤͲͲͲͳ͹ כ ݐ݅݉݁݌݁ݎ݅݌݄݁ݎ݈ܽݒܽݏܿݑ݈ܽݎ݋ݎܿ݁ݎܾ݁ݎ݋ݒܽݏܿݑ݈ܽݎ݀݅ݏ݁ܽݏ݁Ͳ݊݋݌݁ݎ݅݌݄݁ݎ݈ܽݒܽݏܿݑ݈ܽݎ݋ݎܿ݁ݎܾ݁ݎ݋ݒܽݏܿݑ݈ܽݎ݀݅ݏ݁ܽݏ݁
+ ቄെͲǤͲʹ െ ͲǤͲͲͲͲͺ כ ݐ݅݉݁ܾ݀݅ܽ݁ݐ݁ݏͲ݊݋ܾ݀݅ܽ݁ݐ݁ݏ + ቄ
െͲǤͲͻ݈݅ݒ݁ݎ݀݅ݏ݁ܽݏ݁
Ͳ݊݋݈݅ݒ݁ݎ݀݅ݏ݁ܽݏ݁
+ ሺെͲǤͲͶ ൅ ͲǤͲͲͲͲ͹ כ ݐ݅݉݁ሻ݌݁ݎͳ݈݅ݐ݁ݎ݌݋ݏݐ݈݀݅ܽݕݏ݅ݏ݂݈ݑ݅݀݋ݒ݁ݎ݈݋ܽ݀
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Figure 3. Delta analysis for outcome albumin (a) and creatinine (b). Means and standard deviations 
are shown, comparing current values of albumin with baseline values.
Variable Reference group category Estimate Standard Error p-value
Intercept 3.9171 0.01145 <0.001
Time (days) 0.00033 0.00003 <0.001
Baseline predictors
Gender Female Male 0.0966 0.00879 <0.001
Age (years) <56
[56;69) -0.0886 0.01032 <0.001
≥69 -0.2038 0.01038 <0.001
LTI-reference group Normal
Low -0.0925 0.00884 <0.001
High 0.0357 0.02481 0.151
FTI-reference group Normal
Low -0.0796 0.01562 <0.001
High -0.0009 0.01058 0.929
Myocardial Infarction Absent Present 0.0426 0.02240 0.057
Peripheral vascular disease or 
Cerebrovascular disease Absent Present
0.00900 0.01720 0.601
Diabetes with chronic complication Absent Present -0.0233 0.01301 0.074
Liver disease Absent Present -0.0879 0.01777 <0.001
Post-dialysis fluid overload -0.0410 0.00276 <0.001
Predictors over time
Time * (Peripheral vascular disease 
or Cerebrovascular disease) Absent Present
-0.00017 0.00006 0.002
Time * Diabetes with chronic 
complication Absent Present
-0.00008 0.00004 0.064
Time* Post-dialysis fluid overload 0.00007 9.551E-6 <0.001
Table 2. Estimations of the mixed model for the outcome albumin
To give a better understanding of the model results, the above formula is translated 
for a concrete but fictive patient with the following attributes: female, aged 56-68 
years, with low LTI and high FTI, diabetes, and 1 L post-dialysis fluid overload:
ܣ݈ܾݑ݉݅݊ሺݐ݅݉݁ሻ ൌ ͵Ǥͻʹ ൅ ͲǤͲͲͲ͵͵ כ ݐ݅݉݁ െ ͲǤͲͻ െ ͲǤͲͻ ൅ ͲǤͲͷ െ ͲǤͲʹ െ ͲǤͲͲͲͲͺ כ ݐ݅݉݁
൅ሺെͲǤͲͶ ൅ ͲǤͲͲͲͲ͹ כ ݐ݅݉݁ሻ כ ͳ
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ൌ ͵Ǥ͹͵ ൅ ͲǤͲͲͲ͵ʹ כ ݐ݅݉݁
After two years (730 days) of follow up, the albumin level is increased for this patient 
example from 3.73 to 3.96 g/dL.
Variable Reference group category Estimate Standard Error p-value
Intercept 7.8996 0.06047 <0.001
Time (days) 0.001536 0.000131 <0.001
Baseline predictors
Gender Female Male 1.1282 0.04639 <0.001
Age (years) <56
[56;69) -1.0934 0.05456 <0.001
≥69 -2.1196 0.05551 <0.001
LTI-reference group Normal
Low -0.4303 0.04658 <0.001
High 0.2827 0.1318 0.032
FTI-reference group Normal
Low -0.1612 0.08188 0.049
High -0.1444 0.05594 0.010
Congestive heart failure Absent Present -0.2933 0.07254 <0.001
Peripheral vascular disease or 
Cerebrovascular disease Absent Present
-0.3362 0.09098 <0.001
Diabetes with chronic 
complication Absent Present
-0.8736 0.06843 <0.001
Malignancy Absent Present 0.2644 0.09449 0.005
Liver disease Absent Present -0.06052 0.1368 0.658
Post-dialysis fluid overload -0.07915 0.01450 <0.001
Predictors over time
Time* (Peripheral vascular 
disease or Cerebrovascular 
disease)
Absent Present
-0.00051 0.000295 0.081
Time* Diabetes with chronic 
complications Absent Present
0.000402 0.000230 0.081
Time* Liver disease Absent Present -0.00106 0.000454 0.020
Time*Post-dialysis fluid overload Absent Present 0.000142 0.000051 0.005
Table 3. Estimations of the mixed model for the outcome creatinine
Results for creatinine:
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In comparison to their reference categories creatinine is significantly higher for 
males, for patients with high LTI at baseline and for patients with malignancy, 
whereas creatinine is significant lower for patients older/equal than 56, patients with 
congestive heart failure, peripheral vascular or cerebrovascular disease and 
diabetes and patients with low LTI or low and high FTI at baseline. Higher post-
dialysis fluid overload is also associated with lower creatinine level at baseline, but 
regarding the development over the follow up time, higher post-dialysis fluid overload 
at baseline is associated with a greater increase of creatinine. The increase of 
creatinine is higher for patients with liver disease than for patients without liver 
disease. The model results can also be summarized as follows:
Creatinine (time) = 7.90 + 0.00154 * time + ൜ͳǤͳ͵݈݉ܽ݁Ͳ݂݈݁݉ܽ݁ + ൝
െʹǤͳʹ ൒ ͸ͻ
െͳǤͲͻሾͷ͸Ǣ ͸ͻሻ
Ͳ ൏ ͷ͸
+ ൝
െͲǤͶ͵݈݋ݓܮܶܫ
ͲǤʹͺ݄݄݅݃ܮܶܫ
Ͳ݊݋ݎ݈݉ܽܮܶܫ
+ ൝
െͲǤͳ͸݈݋ݓܨܶܫ
െͲǤͳͶ݄݄݅݃ܨܶܫ
Ͳ݊݋ݎ݈݉ܽܨܶܫ
+ 
൜െͲǤʹͻܿ݋݊݃݁ݏݐ݅ݒ݁݄݁ܽݎݐ݂݈ܽ݅ݑݎ݁Ͳ݊݋ܿ݋݊݃݁ݏݐ݅ݒ݁݄݁ܽݎݐ݂݈ܽ݅ݑݎ݁
+ 
൜ െͲǤ͵Ͷ െ ͲǤͲͲͲͷͳ כ ݐ݅݉݁݌݁ݎ݅݌݄݁ݎ݈ܽݒܽݏܿݑ݈ܽݎ݋ݎܿ݁ݎܾ݁ݎ݋ݒܽݏܿݑ݈ܽݎ݀݅ݏ݁ܽݏ݁Ͳ݊݋݌݁ݎ݅݌݄݁ݎ݈ܽݒܽݏܿݑ݈ܽݎ݋ݎܿ݁ݎܾ݁ݎ݋ݒܽݏܿݑ݈ܽݎ݀݅ݏ݁ܽݏ݁
+ቄെͲǤͺ͹ ൅ ͲǤͲͲͲͶͲ כ ݐ݅݉݁ܾ݀݅ܽ݁ݐ݁ݏͲ݊݋ܾ݀݅ܽ݁ݐ݁ݏ + ൜
ͲǤʹ͸ܯ݈ܽ݅݃݊ܽ݊ܿݕ
Ͳ݊݋ܯ݈ܽ݅݃݊ܽ݊ܿݕ
+ ቄെͲǤͲ͸ െ ͲǤͲͲͳͲ͸ כ ݐ݅݉݁݈݅ݒ݁ݎ݀݅ݏ݁ܽݏ݁Ͳ݊݋݈݅ݒ݁ݎ݀݅ݏ݁ܽݏ݁
+ ሺെͲǤͲͺ ൅ ͲǤͲͲͲͳͶ כ ݐ݅݉݁ሻ݌݁ݎͳ݈݅ݐ݁ݎ݌݋ݏݐ݈݀݅ܽݕݏ݅ݏ݂݈ݑ݅݀݋ݒ݁ݎ݈݋ܽ݀
To give a better understanding of these model results, the formula is as follows for a 
concrete but fictive patient with the attributes: female, aged 56-68 years, with low LTI 
and high FTI, diabetes, 1 L post-dialysis fluid overload:
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ܥݎ݁ܽݐ݅݊݅݊݁ሺݐ݅݉݁ሻ ൌ ͹ǤͻͲ ൅ ͲǤͲͲͳͷͶ כ ݐ݅݉݁ െ ͳǤͲͻ െ ͲǤͶ͵ െ ͲǤͳͶ െ ͲǤͺ͹ ൅ ͲǤͲͲͲͶͲ כ
ݐ݅݉݁
൅ሺെͲǤͲͺ ൅ ͲǤͲͲͲͳͶ כ ݐ݅݉݁ሻ כ ͳ
ൌ ͷǤʹͻ ൅ ͲǤͲͲʹͲͺ כ ݐ݅݉݁
After two years (730 days) of follow up, the creatinine level is increased for this 
patient example from 5.29 to 6.81 g/dL.
Discussion
This study showed a significant rate of increase in serum albumin and creatinine 
during the two years following the first 3 months of dialysis, and examined the 
relationship of the trends to demographics, body composition and comorbidities. 
More specifically, evaluating 2 years from baseline to 27 months after initiation of 
dialysis, a significant increase in serum albumin of 0.15 ± 0.45 g/dL was found using 
the delta analysis. Of note, the serum albumin increased most significantly in the first 
6 months. During the first six months on hemodialysis, Parker et al11 reported a 
mean increase of 0.3 g/dL in serum albumin. Evaluating the first 12 months of RRT 
in 266 patients on hemodialysis or peritoneal dialysis, Dalrymple et al9 reported a 
significant but lower increase - about 0.08+0.04 g/dL. This is close to the level 
observed in our study. Since patients with lower albumin and creatinine are more 
likely to die earlier,22,23 increasing trends can result from a positive selection of 
patients. However, also comparing paired values of surviving patients at each time
point, similarly to what was presented in Figures 1 and 2, Parker et al11 were able to 
confirm the rise in serum albumin levels. During the first months on hemodialysis 
many factors can play roles and act in opposite directions. For example, in patients 
with significant proteinuria, the loss of residual renal function will decrease albumin 
loss. However, in parallel, hemoconcentration (resulting from the achievement of a 
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lower hydration status) would increase albumin levels. With the initiation of renal 
replacement therapy, dietary protein intake is expected to improve, but the loss of 
amino acids through the dialysis membrane may negatively affect the protein 
balance. Currently, the almost standard prescription of biocompatible dialysis 
membranes should avoid significant membrane-associated inflammatory stimulus. 
After 3 months from the initiation of hemodialysis, because of a policy of strict 
volume control applied in our dialysis network as evidenced by the low post-dialysis 
fluid overload (0.16±2.13 liters), residual diuresis is expected to be negligible.24
However, in our study the even residual presence of baseline post-dialysis fluid 
overload was still associated with a significantly higher rate of albumin increase, 
showing that hemoconcentration may still play an important role. In long-standing 
hemodialysis patients with negligible renal function, serum albumin has been
reported to decline slowly over time. For example, in a group in prevalent, stable 
patients followed up for 2 years in a study comparing different membranes and 
dialysis technologies, Locatelli et al25 reported a progressive decline of serum 
albumin in the range of 0.11 - 0.22 g/dL. In our study the presence of peripheral and 
cerebrovascular disease was not associated with a significantly different albumin 
value at baseline, but patients with this comorbidity showed a significant negative 
trend during the 2 year follow-up (-0.062±0.022 g/dL per year lower than in patients 
without). The link between vascular disease and plasma proteins has been already 
reported26 and it is associated with inflammation, even if the question whether 
inflammation is the cause or just a marker of an existing disease is still unresolved. 
However, inflammation affects plasma proteins composition and specifically albumin 
levels even more than malnutrition, as already reported by several studies and 
confirmed by our results, since extremely low levels of albumin are nearly always 
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associated with the presence of the acute-phase response.5 Unfortunately, due to a 
very high number of missing values (43 %) C-reactive protein (CRP) could not be 
included in our main analysis. However, as an exercise, we included CRP (<10 
mg/dL; ≥10 mg/dL) as main effect and as interaction with the time (in days) in our 
mixed models. Patients with CRP ≥10 mg/dL had significantly lower albumin (-
0.1355 mg/dL difference, p-value<0.001), but had a significantly higher albumin 
increase over the follow-up time (by 0.00019 per day, p-value<0.001). No significant 
effect was found for creatinine, neither for the main effect of CRP nor for the 
interaction term. Finally, it has to be mentioned that, as already reported by 
Dalrymple et al,9 males had a significantly higher serum albumin than females 
(+0.097+0.009 g/dL) as well as did patients younger than 56 years in comparison to 
those of ≥56-<69 and ≥69 years (+0.089±0.010 g/dL and +0.204±0.010 g/dL, 
respectively), but no significant difference in rates were detected during the 2-year 
follow-up. 
Diabetes was associated with a borderline lower baseline albumin level (-
0.0233+0.0130 g/dL difference, p= 0.074) and also during the 2-year follow-up 
diabetics showed a borderline lower increasing rate (-0.0292+0.0146 g/dL per year 
difference, p= 0.064). Dalrymple et al,9 probably because of a lower sample size, 
however reported that diabetes was not statistically associated with a different level 
of albumin, neither at baseline nor during the follow-up. 
In regards to serum creatinine, this study showed a significant increase of 0.84 ± 
1.94 mg/dL in the first year, mainly in the first 6 months of the study follow-up (from 
the baseline of 3 to 9 months after the initiation of extracorporeal dialysis). Similarly, 
Culp et al4 showed an initial increase of serum creatinine from the baseline (mean, 
SE) of 8.56+3.35 to 9.52+3.58 and to 10.16+3.55 mg/dL after 6 and 12 months of 
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follow-up, respectively. Their values after 2 and 3 years were not significantly 
different (10.54+3.39 and 10.97+3.58 mg/dL, respectively). Jadoul et al27 reported 
that, in a series of 15 incident patients on hemodialysis trice a week, serum 
creatinine after an initial slight increase declined on average by 19.6% after 5-years 
of follow-up; the decline correlated with age. The cause of the increasing creatinine 
level in incident dialysis patients during the first 6-month of follow-up on dialysis is 
very likely to be due not only to the increase of protein intake due to an improved 
appetite, but also the parallel decline in residual renal function, mainly occurring in 
earlier phases of maintenance hemodialysis.28 Patients with liver disease did not 
show statistically different levels of baseline serum creatinine but a significantly lower 
rate of increase compared to those without this comorbid condition during the 2-year 
follow-up. The decline in hepatic functional capacity results in decreased creatine 
production. In addition, patients with liver disease are known to have less skeletal 
muscle mass, resulting in diminished creatine storage and lower conversion of 
creatine to creatinine.29 Therefore, the significant lower change rate in the level of 
serum creatinine during the 2 years of follow-up in patients with liver disease can be 
considered an expected result. The direct relationship between muscle mass and 
serum creatinine level was also confirmed by the significant 0.430+0.047 mg/dL 
lower creatinine level in patients with baseline lean tissue index below the 10th
percentile in respect of normal 10th to 90th range of the normal population distribution 
by age and gender. On the other hand, patients with a lean tissue index beyond the 
90th percentile showed a significantly higher serum creatinine level in the range of 
0.283+0.132 mg/dL. However, despite the fact that lean tissue index has been 
reported to decline by about 0.4 kg/m2 during the 2-year follow-up in incident patients 
from a baseline of 6 month to 30 months,30 this did not significantly affect the trend of 
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serum creatinine in our study, probably because magnitude was not the most 
relevant factor.
The presence of diabetes and of vascular diseases were both associated with a 
significantly lower serum creatinine compared to those patients without these 
comorbidities (-0.874+0.068 and -0.336+0.091 mg/dL differences, respectively). In 
addition, diabetics showed a borderline higher increase and patients with vascular 
disease a comparable borderline lower increase during the 2-year follow-up. 
Creatinine clearance is expected to be very low from 3 to 27 months after the start of 
extra-corporeal dialysis, probably in the range of 1 to 8 mL/min4 and without relevant 
differences between different dialysis modalities. Therefore, higher levels of pre-
dialysis creatinine can be found in patients who either receive a lower dialysis dose 
or whose superior nutritional status sustains an increased musculature. As already 
mentioned, in the presence of vascular disease and inflammation, the higher risk of 
malnutrition could already explain the current results. In diabetics, poorer dialysis 
tolerance with more frequent predialytic symptoms, such as nausea and vomiting, 
has been reported.31 Whether the higher rate of intra-dialysis symptoms actually 
compromises the dialysis dose in term of small molecules, with consequent higher 
increase of creatinine, is still open for proof.
Finally, also for creatinine the presence of post-dialysis fluid overload at the 3-month 
baseline was associated with lower creatinine level and a higher increase during the 
2-year follow-up, probably reflecting the correction of dry body weight.
This study has limitations associated with its retrospective and observational nature. 
The exclusion of catheter patients reduces the generalizability of the findings. Of 
particular note are the absence of data on residual renal function and the paucity of 
data on C-reactive protein and serum bicarbonate. The strength of the study lies in 
Protein dynamics in the first 2 years of dialysis
97
the broad geographical distribution in Europe, Middle East and Latin America, 
ensuring a certain generalizability of the results, as well as in the selection of 
patients on a homogeneous treatment (i.e. all have three times weekly 4-hour 
dialysis sessions, treatment by fistula or graft, adequate dialysis dose, and strict fluid 
overload management according to the treatment protocol of the dialysis chain 
network). 
Conclusions 
This study showed that serum albumin and creatinine levels, which belong to the 
strongest independent predictors of survival in hemodialysis patients,4,32 improved in 
patients treated according to a good dialysis protocol. The presence of fluid overload 
and certain comorbidities, such as vascular disease, liver disease and maybe 
diabetes, may modify the trends. Therefore, monitoring of such visceral and somatic 
proteins remains of high priority in the follow-up of patients on renal replacement 
therapy, independent of the need for comprehensive and regular assessments of 
body composition. 
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Practical Application
In the two years after the start of dialysis therapy, serum albumin and creatinine 
levels increased in this cohort of 3,860 incident dialysis patients. The presence of 
post-dialysis fluid overload and certain comorbidities, such as vascular disease, liver 
disease and diabetes, modified these positive trends. Given that albumin and 
creatinine are predictors of both nutritional status and mortality, and that many 
dialysis patients suffer from protein energy wasting already in the initial phase of the 
renal replacement therapy, these results show the importance of monitoring such 
visceral and somatic proteins from the beginning of dialysis therapy.
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Abstract
Background/Aim
The neutrophil-to-lymphocyte ratio (NLR), defined as the neutrophil count divided by lymphocyte 
count, is an inexpensive and readily available parameter, which may serve as a surrogate for 
inflammation markers, such as C-reactive protein (CRP). The aim of this study was to determine the 
utility of NLR in the prediction of elevated CRP levels in hemodialysis (HD) patients.
Methods
We analyzed 43,272 HD patients from 2 distinct cohorts within the Monitoring Dialysis Outcomes 
research collaboration in whom contemporaneous measurements of neutrophil and lymphocyte 
counts, serum albumin and CRP levels were available. Logistic regression was used to determine the 
relationship of trichotomized NLR (<2.5, 2.5–5 and >5.0) and albumin levels (<3.1, 3.1–4.0 and >4.0 
g/dl) with elevated CRP levels (>10.0, >20.0 and >30.0 mg/l). Congruence of the prediction models 
was examined by comparing the regression parameters and by cross-validating each regression 
equation within the other cohort. 
Results
We found that NLR >5.0 vs. <2.5 (cohort 1: OR 2.3; p < 0.0001 and cohort 2: OR 2.0; p < 0.0001) was 
associated with CRP levels >10.0 mg/l. Stepwise increase in odds ratio for CRP >10.0 mg/l was 
observed with the combination of high NLR and low albumin levels (NLR >5.0 and albumin <3.1) 
(cohort 1: OR 7.6; p < 0.0001 and cohort 2: OR 11.9; p < 0.0001). Cross-validation of the 2 regression 
models revealed a predictive accuracy of 0.68 and 0.69 in the respective cohorts.
Conclusion
This study suggests that NLR could serve as a potential surrogate marker for CRP. Our results may 
add to diagnostic abilities in settings where CRP is not measured routinely in HD patients. NLR is 
easy to integrate into daily practice and may be used as a marker of systemic inflammation.
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Introduction
Cardiovascular events, infections, anemia and malnutrition are well recognized 
complications in hemodialysis (HD) patients and are associated with increased morbidity and 
mortality1-5. The underlying causes for the development of these complications are complex, 
multifactorial and poorly understood. Over the past decade, there has been increasing 
evidence linking oxidative stress and inflammation with multiple disease states including 
myocardial infarction and stroke6,7. Several studies in the chronic HD patient population have 
shown elevated levels of circulating inflammatory markers, suggesting susceptibility for both 
micro and macro vascular complications8,9. Various biomarkers including total lymphocyte 
count, C-reactive protein (CRP), interleukin (IL)-6, IL-18, tumor necrosis factor-α (TNF-α), 
pentraxin-3, and proteases such as matrix metalloproteinase-9 have been proposed to 
measure systemic inflammation and are associated with increased hospitalization trends and 
mortality in HD patients10-21. CRP, an acute-phase reactant, has emerged as the most 
widespread inflammatory biomarker for clinical use. CRP is chemically stable and has a 
relatively long half-life without diurnal variation22,23. Recently, neutrophil-to-lymphocyte ratio 
(NLR) has been increasingly recognized as a marker of systemic inflammation in oncology 
and cardiology literature, where elevated levels of NLR have been reported to be associated 
with poor outcomes24-26. We have recently shown that elevated NLR may also be linked with 
poor prognosis in chronic HD patients. However, there is scarcity of clinical studies 
concerning NLR and its relationship to other inflammatory biomarkers. The aim of our study 
was to evaluate whether NLR correlated with CRP levels. Furthermore, we aimed at 
determining whether a combination of inflammatory markers (NLR and albumin levels) 
improves prediction of CRP levels in chronic HD patients. We suggest that NLR can be a 
surrogate marker of systemic inflammation and serve as a useful tool to identify subgroups 
of patients who are at a heightened risk of cardiovascular and non-cardiovascular 
complications. Additionally, NLR because of its easy availability and cost-efficiency may be 
used to assist physicians and nephrologists to evaluate nutritional and cardiovascular status 
and prognostic outcome in HD patients in locations where CRP is not available.
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Material and Methods
Study Population
This cross-sectional and retrospective study was conducted at the Renal Research Institute, 
New York, N.Y., USA. Patients included in this study were part of MONDO (Monitoring 
Dialysis Outcomes). MONDO is a global, multicenter research collaboration that was 
designed to explore the determinants of patient survival in worldwide HD population, where 
longitudinal clinical data were collected in 148,772 patients from 27 countries in 5 continents 
(Asia, Europe, North America, South America and Australia)27. The institutional review board 
committee at each of the participant institutions approved the study independently. Informed 
consent was
obtained as required in each country. This analysis was restricted to HD patients with 
available demographic information (age, sex and dialysis vintage) and contemporaneous 
laboratory parameters (serum albumin, neutrophil count, lymphocyte count and CRP levels).
Consequently, the study population comprised a sample of 27,326 HD patients from 
Fresenius Medical Care (FMC) clinics in 17 European countries (cohort 1) and 15,946 HD 
patients from Kuratorium fur Heimdialyse (KfH) centers in Germany (cohort 2).
Data Collection and Measurements
The independent variables of interest were NLR and albumin levels. Total white cell count, 
neutrophils and lymphocytes counts were determined using an automated blood cell 
counter. NLR was calculated as a simple ratio between the absolute neutrophil and the 
absolute lymphocyte counts. The same blood samples were analyzed to measure albumin 
levels according to local laboratory standards by one of the following methodologies: 
nephelometry, bromocresol green or bromocresol purple (Sigma-Aldrich, St. Louis, Mo., 
USA)28,29. Bromocresol purple measurements were later converted to the bromocresol green 
method30. The independent variables NLR and albumin levels were trichotomized (NLR 
<2.5, 2.5–5 and >5.0 and albumin <3.1, 3.1–4.0 and >4.0 g/dl) based on practical clinical 
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cut-off points described in the literature31,32. The primary dependent variable was CRP 
measured in mg/l. CRP values were trichotomized at (>10.0, >20.0 and >30.0 mg/l). These 
cut-offs were selected based on reference ranges for CRP reported in literature33,34. We 
have chosen categorization because it is easier to interpret and also because of its simplicity
in reporting results.
Statistical Analysis
A logistic regression was used to determine the relationship of trichotomized NLR and 
albumin levels, respectively, with elevated CRP levels (>10.0, >20.0 and >30.0 mg/l) as an 
outcome variable.
Continuous variables were expressed as the mean (SD) or median and interquartile range 
(IQR). Categorical variables were expressed as absolute (n) and relative (%) frequency. 
Natural log transformation was applied to non-normal distributions. Spearman rank 
correlation was used to examine the relationship between continuous variables (NLR and 
CRP). A forward stepwise logistic regression model was developed to determine the 
relationship between trichotomized NLR (<2.5, 2.5–5 and >5.0) and albumin levels 
(<3.1, 3.1–4.0 and >4.0 g/day), respectively, with elevated CRP levels (>10.0, >20.0 
and >30.0 mg/l), adjusting for confounders including age, sex and dialysis vintage. 
The entry and retention p value thresholds were set at p < 0.05 and p < 0.1, 
respectively.
Statistical analysis was performed using SPSS software version 17.0 (SPSS, 
Chicago, Ill., USA) and R (version 2.12.0). A 2-tailed p value <0.05 was considered 
statistically significant.
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Results
Baseline characteristics of both cohorts are shown in table 1. In cohort 1, 27,326 
patients enrolled with the mean age of 63.5 years (SD 15.2), and 16,251 (60.4%) 
were male. Cohort 2 consisted of 15,946 patients with a mean age of 63.1 years (SD 
16.5), and 9,503 (59.6%) were male.
The median dialysis vintages in both cohorts were 33.2 months (IQR 11.3–73.7 
months) and 13.0 months (IQR 4.0–44.0 months), respectively. The mean total 
leukocyte, absolute neutrophil and absolute lymphocyte counts in cohorts 1 and 2 
were 6.9 ± 2.5 x 109/l, 4.3 ± 2.1 x 109/l and 1.6 ± 0.9 x 109/l and 7.6 ± 10.5 x 109/l, 
5.0 ± 7.1 x 109/l and 1.5 ± 3.1 x 109/l, respectively (table 1).
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Bivariate correlation analysis showed a significant positive correlation between NLR 
and CRP in cohort 1 (Spearman rank correlation ρ = 0.23; p < 0.0001) and negative
association between NLR and serum albumin levels in both cohorts (ρ = –0.18 and ρ 
= –0.27; p < 0.0001, respectively). Correlation between NLR and CRP was 0.04 in 
cohort 2. Stepwise multiple logistic regression analysis for both cohorts showed that 
high levels of NLR are independently associated with high CRP levels (>10.0 mg/l) 
(NLR >5.0 vs. <2.5; adjusted OR 2.3, 95% CI 2.1–2.6; p < 0.0001 and adjusted OR 
2.0, 95% CI 1.8–2.4; p < 0.0001, respectively; table 2 a, b). Similarly, low levels of 
albumin were associated with high CRP levels (albumin <3.1 vs. >4.0 g/dl; cohort 1: 
adjusted OR 3.39, 95% CI 2.99–3.85; p < 0.0001 and cohort 2: adjusted OR 5.59, 
95% CI 4.94–6.33; p < 0.0001). There was stepwise increase in odds ratio for high 
CRP (>10.0 mg/l) with stepwise increase in NLR and low albumin levels in both 
study cohorts (table 3 a, b).
When CRP cut-off values were increased (>10.0, >20.0 and >30.0 mg/l), odds of 
prediction improved in both the study cohorts (fig. 1).
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Cross validation of the 2 regression models for CRP cut-off >10.0 mg/l revealed 
predictive accuracy of 0.68 (95% CI 0.67–0.69) for prediction in cohort 2 and 0.69
(95% CI 0.68–0.70) for prediction in cohort 1, respectively (fig. 2). The predictive 
models exhibited a higher and statistically significant diagnostic accuracy with higher
CRP cut-off points in both study cohorts (fig. 2).
Discussion
In this study, a statistically significant positive association was found between NLR 
and CRP levels in the MONDO cohort. This result is not surprising because
leukocytes have long been recognized as principal effectors cell in the acute 
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inflammatory reaction35. 
Experimental models have shown that inflammatory cells, mainly neutrophils, 
possibly regulate CRP levels through secretion of pro-inflammatory cytokine TNF-α 
and IL-636. In fact, cellular immune response to infection is characterized by the 
elevation of neutrophil count and decline in lymphocyte count37. Recently, Turkmen 
et al.38 have shown positive correlation between NLR and TNF-α in HD patients. In 
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this study, serum albumin levels were negatively correlated with both NLR and CRP 
levels. These findings are consistent with the published literature that albumin 
behaves as a negative acute phase protein and also support the concept of 
Malnutrition-Inflammation Complex in HD patients39,40.
One of the findings of this study is that high NLR significantly predicts high CRP 
levels (NLR >5.0 vs. <2.5; cohort 1: OR 3.9, 95% CI 3.5–4.2; p < 0.0001 and cohort 
2: OR 3.2, 95% CI 3.0–3.6; p < 0.0001) in HD patients. A high CRP level was 
defined as values >10 mg/dl. This relationship remains materially unchanged even 
after adjusting for age, gender and dialysis vintage (NLR >5.0 vs. <2.5; cohort 1: 
adjusted OR 2.3, 95% CI 2.1–2.6; p < 0.0001 and cohort 2: adjusted OR 2.0, 95% CI 
1.8–2.4; p < 0.0001, respectively). Interestingly, in the multivariate regression model, 
absolute neutrophil and absolute lymphocyte counts separately were not strongly 
associated with high CRP levels as compared to NLR. There is also evidence about 
a similar trend in relationship between absolute neutrophil and lymphocyte counts 
and serum TNF-α37. These findings are clinically relevant, suggesting NLR to be a 
better predictor of CRP than the total number of white cell count.
We also found an additive relationship between albumin and NLR levels in terms of 
predicting an individual likelihood of high CRP level. As shown in table 3 a, subjects 
with high NLR and low albumin levels (NLR >5.0 and albumin level <3.1 g/dl) had a 
7.6-fold greater odds of having elevated CRP level >10 mg/l (95% CI 5.5–9.9) as 
compared to the 2-fold odds with high NLR alone (95% CI 1.7–2.4) and the 3.39-fold 
odds with low albumin alone (95% CI 2.99–3.85) in cohort 1 (table 2 a). Similar 
trends were seen in cohort 2 (tables 2 b and 3 b). In this study, we showed that the 
regression model derived from NLR and albumin can predict CRP levels in HD 
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population with an area under an ROC curve of 0.68 and 0.69 in 2 different cohorts 
(fig. 2).
We suggest that the use of an NLR as an inflammatory biomarker in HD patients has 
significant diagnostic benefits. Considering the short half-life of neutrophils, NLR can 
be used as an effective marker of acute inflammation and reflect the intensity of 
systemic inflammation. Serial measurements of NLR may be used to identify HD 
patients at high risk for an adverse outcome and thus help in informed medical 
decision making. Recent studies have suggested that the epidemiological 
association of CRP with cardiovascular events is widely exaggerated41-45. In fact, 
other inflammatory markers, including serum albumin and leukocyte count, have 
shown similar associations with cardiovascular disease risk41-45. A systemic 
approach incorporating NLR with other inflammatory biomarkers and traditional risk 
factors may improve the diagnostic accuracy of cardiovascular and non-
cardiovascular risk prediction models. In addition, NLR may also be used as a tool to 
monitor the effect of anti-inflammatory therapies46. Most importantly, NLR is routinely 
available and easy and inexpensive to measure, and thus could be used as a cost-
effective surrogate to CRP in dialysis units (approximate CBC with differential cost 
per sample; Europe: EUR 3.50 and United states: USD 4.25; CRP cost per sample; 
Europe: EUR 11.66 and United States: USD 7.04); it can also be used in resource 
limited settings lacking the facility for measuring CRP for therapeutic decision 
making. An additional consideration is the fact that in most European countries, CPR 
is measured no more than once a month on a routine basis, limiting its utility to 
detect inflammation at the right time.
This study has several strengths. This was a multicenter study with a large sample 
size and wide geographic representation, thus increasing the generalization of the 
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results. The study also has limitations. First, it was a cross-sectional analysis 
because NLR, albumin and CRP levels were considered only once in our study. 
Second, the majority of the patient population was Caucasian. Also, leukocyte and 
neutrophil counts are nonspecific and have high false-positive and false-negative 
rates to predict cardiovascular complications47.
In summary, the results of the present study highlight the relationship between NLR, 
albumin and CRP levels. It is shown that NLR may be a surrogate marker of 
systemic inflammation in its ability to predict CRP levels. Addition of albumin to NLR 
substantially improves the prediction of CRP. NLR may not be the best available 
laboratory-based assay to measure inflammation. However, from a pragmatic 
standpoint, it can certainly be a useful assay for systemic inflammation in resource-
limited settings. In-depth and epidemiological studies of high standards are further 
required to establish the potential clinical utility and applicability of NLR. Further 
studies are also warranted to assess the contributing role of albumin and NLR in 
predicting other inflammatory biomarkers. Lastly, it will be interesting to study if NLR 
can provide independent prognostic information over and above that provided by 
inflammatory biomarkers such as CRP.
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Abstract
Background and objectives
High body mass index appears protective in hemodialysis patients, but uncertainty prevails regarding 
which components of body composition, fat or lean body mass, are primarily associated with survival.
Design, setting, participants, & measurements
Data between April 2006 and December 2012 were extracted from the Fresenius Medical Care 
Europe subset of the international MONitoring Dialysis Outcomes initiative. Fresenius Medical Care 
Europe archives a unique repository of predialysis body composition measurements determined by 
multifrequency bioimpedance (BCM Body Composition Monitor). The BCM Body Composition Monitor 
reports lean tissue indices (LTIs) and fat tissue indices (FTIs), which are the respective tissue masses 
normalized to height squared, relative to an age- and sex-matched healthy population. The 
relationship between LTI and FTI and all-cause mortality was studied by Kaplan–Meier analysis, 
multivariate Cox regression, and smoothing spline ANOVA logistic regression.
Results
In 37,345 hemodialysis patients, median (25th–75th percentile) LTI and FTI were 12.2 (10.3–14.5) 
and 9.8 (6.6–12.4) kg/m2, respectively. Median (25th–75th percentile) follow-up time was 266 (132–
379) days; 3458 (9.2%) patients died during follow-up. Mortality was lowest with both LTI and FTI in 
the 10th–90th percentile (reference group) and significantly higher at the lower LTI and FTI extreme 
(hazard ratio [HR], 3.37; 95%confidence interval [95% CI], 2.94 to 3.87; P<0.001). Survival was best 
with LTI between 15 and 20 kg/m2 and FTI between 4 and 15 kg/m2 (probability of death during 
follow-up: ,5%). When taking the relation between both compartments into account, the interaction 
was significant (P=0.01). Higher FTI appeared protective in patients with low LTI (HR, 3.37; 95% CI, 
2.94 to 3.87; P<0.001 at low LTI–low FTI, decreasing to HR, 1.79; 95% CI, 1.47 to 2.17; P<0.001 at 
low LTI–high FTI).
Conclusions
This large international study indicates best survival in patients with both LTI and FTI in the 10th–90th 
percentiles of a healthy population. In analyses of body composition, both lean tissue and fat tissue 
compartments and also their relationship should be considered.
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Introduction
Contrary to the general population, higher body mass index (BMI) in hemodialysis 
(HD) patients is associated with better survival1. Similar results were found in older 
adults and in many chronic diseases2-6. Numerous HD studies have addressed this 
phenomenon, with largely inconsistent results. Discrepancy exists even regarding 
the upper BMI limit for survival advantage, with some studies reporting a positive 
effect even at BMI values >35 kg/m2 and others indicating an upper limit of 25 kg/m2 
7,8.
Postulated reasons for improved survival with high BMI include potential benefits of 
adipose tissue per se, for example as a source of TNF-–soluble receptors and 
lipoproteins that counteract the effects of TNF-itself or the inflammatory effects of 
circulating endotoxins8-10 or as a vital energy source in undernourished patients10. In 
health, aging is associated with loss of muscle mass in the range of 2–4 kg over 10 
years11.
This physiologic process is believed to precede at a faster rate in patients with ESRD 
where several catabolic factors accelerate muscle wasting12,13. In addition, anabolic 
pathways are compromised by low testosterone levels14 and abnormalities in the 
insulin growth factor–1 pathways15,16. It is therefore not surprising that patients with 
ESRD develop protein energy wasting (PEW), not because of reduction in fat mass, 
but because of loss of lean tissue. PEW is present in 18%–75% of patients with
CKD17,18.
BMI measures do not differentiate between fat and lean body mass so it is
challenging to understand quantitatively which components of body composition are 
related to survival in patients with ESRD: fat tissue mass (FTM), lean tissue mass 
(LTM), or both.
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Studies with surrogate markers of FTM and LTM suggest a dominant protective role 
of LTM over FTM7,17,19,20.
However, other studies concluded that survival is dependent more on FTM than 
LTM10,21. Recently, multifrequency bioimpedance spectroscopy (MF-BIS) devices 
have been introduced to assess body composition in HD patients. MF-BIS directly 
measures FTM and LTM on a routine basis. In this study, predialysis standard of 
care body composition assessed by MF-BIS was used to explore the relationship 
between lean tissue, fat tissue, and survival.
Materials and Methods
The MONitoring Dialysis Outcomes initiative comprises HD databases from Renal 
Research Institute clinics in the United States; Fresenius Medical Care (FMC) clinics 
in Europe, Asia Pacific, and Latin America; KfH clinics in Germany; and clinics 
associated with the Imperial College (United Kingdom), Hadassah Medical Center 
(Israel), and Maastricht University Medical Center (The Netherlands)22. Electronic 
medical records are assembled in a primary database after obtaining informed 
consent and in accordance with local privacy and data protection regulations.
For this study, data from European FMC clinics were extracted for all patients who 
had at least one routine measurement using the BCM Body Composition Monitor 
(FMC, Bad Homburg, Germany) between April 1, 2006, and December 31, 201223. In 
contrast to earlier bioimpedance methodologies, the BCM Body Composition Monitor 
expresses body composition as a three-compartment model, providing 
overhydration, lean tissue index (LTI), and fat tissue index (FTI), whereby LTI and 
FTI are the respective tissue masses normalized to height squared. Also, LTI and 
FTI percentiles (<10th percentile [low]; 10th–90th percentile [normal]; and >90th 
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percentile [high]) relative to an age- and sex-matched healthy population are 
supplied. The three compartment model of the BCM Body Composition Monitor has 
been validated against standard reference methods for assessment of fluid status 
and body composition in dialysis patients, albeit partly against gold standard 
techniques in healthy controls only24-27.
Baseline was defined as the first BCM Body Composition Monitor measurement 
available for a patient in the study period (April 1, 2006–December 31, 2012). All 
other values were averaged for the period 630 days of the first BCM Body 
Composition Monitor measurement. Measurements were performed predialysis.
Statistical Analyses
Primary outcome was all-cause death. In survival analysis, baseline values of LTI 
and FTI were entered as categorical variables. Univariate Kaplan–Meier analyses 
were conducted to explore the association of combinations of LTI and FTI categories 
and the time between first body composition measurement and death. Survival 
differences between groups were assessed using the log-rank test. Multivariate Cox 
proportional-hazard models adjusted for age, sex, and dialysis vintage assessed the 
association of LTI, FTI, and different FTI/LTI category combinations with mortality. 
The robustness of the results was tested with sensitivity analyses controlling for Kt/V 
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and restricted to patients with dialysis vintage <6 months. Cox proportional hazards 
and linearity assumptions were confirmed using diagnostic plots of scaled
Schoenfeld and Martingale residuals. Censoring events were transfer to non-FMC 
clinics, transplantation, or study end on December 31, 2012. To confirm the results, 
we fitted a smoothing spline ANOVA logistic regression model for the probability of 
death 1 year later. This treats both LTI and FTI as continuous variables and allows 
the data to decide the joint effect of LTI and FTI. The same covariates as included in 
the Cox regression analysis were included in the spline model. In addition, sex-
specific spline analyses were also performed to test the observations pertaining to 
the relationship between BMI and FTI. The R package gss was used to fit the 
smoothing spline ANOVA model. A P value <0.05 was considered significant. 
Analyses were performed with SAS version 9.3 (Cary, NC) and R statistics software 
system version 3.0.2.
Results
We analyzed data from 37,345 HD patients (57% men) from 380 clinics in the 
following 17 European countries: Bosnia and Herzegovina, Czech Republic, France, 
Hungary, Ireland, Italy, Poland, Portugal, Romania, Russia, Serbia, Slovakia, 
Slovenia, Spain, Sweden, Turkey, and the United Kingdom. At the time of first body 
composition measurement, mean patient age was 62.7+15.2 years, and mean BMI 
was 26.0+5.3 kg/m2. Median (25th–75th percentile) follow-up time was 266 (132–
379) days. Median (25th–75th percentile) of LTI and FTI were 12.2 (10.3–14.5) kg/m2
and 9.8 (6.6–12.4) kg/m2, respectively. Between the first body composition 
measurement and study end 3458 (9.2%) patients died.
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Table 1 shows key patient characteristics, inflammation markers, and nutritional 
parameters at baseline and nine distinct body composition categories: (1) low LTI 
and low FTI; (2) low LTI and normal FTI; (3) low LTI and high FTI; (4) normal LTI and 
low FTI; (5) normal LTI and normal FTI; (6) normal LTI and high FTI; (7) high LTI and 
low FTI; (8) high LTI and normal FTI; and (9) high LTI and high FTI. Although 85% of 
patients had a normal FTI, almost 50% had low LTI (Table 1). Reliable data on 
residual renal function were not available.
Of the six groups with normal or high FTI, BMI values were higher than the cohort 
average value (i.e., 26.0+5.3 kg/m2) in five groups (41.3% of the study population). A
BMI value slightly lower than the cohort average was observed for the remaining 
group with normal FTI and low LTI (39.1% of the study population; BMI, 25.41+3.89 
kg/m2). Sex-specific spline analyses of the relationship between BMI and FTI 
revealed that BMI increases with increasing FTI (Supplemental Figures 1 and 2). Of 
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the six groups with normal or high LTI, BMI values were higher than the cohort 
average in four groups (37.8% of the study population). Lower than cohort average 
BMI was observed for the remaining two groups with low FTI (15.3% of the study 
population). Table 2 provides a summary of the BMI categories as defined by the 
World Health Organization (WHO) (in 2004) and the LTI and FTI groups analyzed in 
this study. BMI levels were higher than one would expect given the lean and fat
tissue amounts: respectively, 20% and 47% of patients had FTI and LTI below the 
10th percentile, but they had normal to obese BMI levels.
Univariate Kaplan–Meier analyses indicated a survival benefit for patients with 
normal LTI and concomitant normal FTI. The worst survival was observed for 
patients with a combination of low LTI and low FTI. The results of the multivariate 
Cox proportional-hazard analyses are presented in Table 3. First, we constructed
three explanatory models with LTI and FTI as categorical variables and with normal 
FTI and normal LTI as references. Model 1 included LTI but not FTI; model 2 
included FTI but not LTI; and model 3 included combinations of LTI and FTI 
categories. Model 1 indicated that both low and high LTIs were associated with 
higher mortality (hazard ratio [HR], 1.68; 95% confidence interval [95% CI], 1.56 to
1.80; P<0.001 and HR, 1.20; 95% CI, 1.01 to 1.41; P=0.03, respectively). Model 2 
indicated that also both low and high FTIs were associated with higher mortality (HR, 
1.34; 95% CI, 1.24 to 1.45; P<0.001 and HR, 1.19; 95% CI, 1.01 to 1.40; P=0.03, 
respectively). Model 3 indicated the highest HR for the combination of low LTI and 
low FTI; the lowest HR was for normal LTI and FTI. Sensitivity analyses controlling 
for Kt/V and restricting dialysis vintage confirmed the robustness of these results 
(data not shown).
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All three explanatory models were only adjusted for age, sex, and vintage to avoid 
collinearity, but the addition of other potential variables were included in a predictive 
model (fully adjusted model, Table 3): only the statistical significance at high LTI–low 
FTI was reduced. Next we conducted a 1-year survival analysis for the joint effect of 
LTI and FTI as continuous variables. The contour plot of the estimated death 
probability as a function of LTI and FTI with other covariates fixed on the basis of the 
smoothing spline ANOVA logistic regression model is shown in Figure 1. The result 
of FTI and LTI slices through the contour plot at discrete LTI and FTI values (5, 10, 
15, 20, and 25 kg/m2) are displayed in Figures 2 and 3, respectively. The results
corroborate the Cox regression results, revealing optimal survival at LTI and FTI in 
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the middle ranges. However, although the range 15–20 kg/m2 appeared optimal for 
LTI, the optimal range for FTI appeared to be lower (4–15 kg/m2).
Discussion
In this study of prevalent HD patients, body composition was determined as part of 
standard of care using a validated multifrequency bioimpedance device. LTI and FTI 
within the 10th–90th percentile of an age- and sex matched healthy population were 
associated with best survival, whereas low FTI and low LTI, and especially the 
combination of both, were associated with higher mortality. The average patient BMI 
was 26.0+15.2 kg/m2, which is overweight for the general population (normal BMI 
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defined by WHO: 18.5–24.9 kg/m2). In fact, the BMI distribution was found to 
approximately parallel the FTI distribution, but starting already at WHO normal status 
and progressing to overweight and then even obese: irrespective of LTI, patients 
with low FTI had on average a WHO normal BMI (normal, 18.5–24.9 kg/m2); patients 
with normal FTI had a high WHO BMI (overweight, 25–29.9 kg/m2); and patients with 
high FTI were obese according to the WHO classification (30 to >40 kg/m2) (Table 
2). This observation, which was also confirmed by sex-specific analyses, indicates a 
shift toward higher BMIs in this HD population and can explain some previous 
interpretations of a protective effect of high BMI per se. Furthermore, patients in our 
study with even a low LTI did not appear to be underweight, but rather to have 
normal weight or even be obese according to the WHO BMI classification. Therefore, 
BMIs of HD patients are incompletely informative in predicting body composition. 
This can only be partially explained by the effect of fluid loading on BMI in dialysis 
patients (e.g., approximately +0.6 kg/m2 for an interdialytic weight gain from 75 to 77 
kg in a patient of height 1.75 m), but appears to be mainly related to an altered 
relation between fat and lean tissue in this population.
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These findings add valuable insight to understanding the observation that HD 
patients with high BMI experience a better survival compared with fellow patients 
with lower BMI. In essence, our results indicate that body composition, and not just 
BMI, is related to outcome and that patients with the same BMI but different ratios of 
lean to fat mass may have different outcomes. The robustness of the result was 
tested with various models incorporating LTI and FTI as categorical and continuous 
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variables and by a sensitivity analysis when Kt/V is controlled for or when restricted 
to patients with dialysis vintage <6 months.
Almost half of the patients in our study had LTIs below the 10th percentile of an age-
and sex-matched healthy population, whereas only 4.5% had LTIs above the 90th
percentile (Table 1). Low lean body mass is a component of the PEW syndrome, and 
it is thought to be associated with a parallel decrease in BMI. However, our results
show that most patients with low LTI had normal FTI and BMI levels ranging 
between normal and obese. Honda et al. demonstrated that low lean BMI (defined in 
their study as lean body mass determined by dual energy x-ray absorptiometry and 
divided by height squared) is not exclusively a characteristic of patients with low 
BMI21.
In fact, the prevalence of patients with PEW according to the Subjective Global 
Assessment was 60% in patients with a BMI<20 kg/m2, 39% in patients in the normal 
20–25 kg/m2 group, and 16% in patients in the overweight group (BMI 25–29.9 
kg/m2). Patients with PEW in the latter group were characterized by a higher fat BMI 
over lean BMI, a condition labeled obese sarcopenia. On the basis of the current 
findings, we suggest that the presence of a normal BMI is insufficient to refute 
diagnose of malnutrition and that LTI, FTI, and their relation must be taken into 
account.
Knowledge of predictors of low and high LTI and FTI may help to develop 
interventional corrective strategies. Inflammatory markers are known to be higher in 
patients with PEW; therefore, it is not surprising that a low LTI is associated with 
mortality21. This relationship suggests that malnourished (even obese) HD patients 
have a low LTI because of the catabolic effects of inflammatory mediators. The C-
reactive protein levels in Table 1 support this. It has also recently been demonstrated 
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that an excess of fat mass in obese patients can amplify the oxidative stress and
inflammation caused by renal insufficiency28. This is in line with the results of our 
model 2, but not model 3 (whereby the latter may be because of the small numbers 
of patients in the upper categories). As shown in this study, the relation between LTI 
and FTI has to be taken into account. In patients with normal LTI, higher FTI was
associated with a borderline significant outcome (P=0.06) compared with normal FTI, 
and in patients with low LTI it was associated with improved outcome. Fat mass can 
also serve as an energy reservoir in case of energy depletion, which might provide 
an explanation for the latter phenomenon because patients with low LTI are likely to 
be protein-energy wasted. Therefore, there may be a discrepancy between the long-
term health risks with increased fat mass and short-term positive effects of higher fat 
mass in patients with low LTI and protein energy wasting10,29.
Interventions aimed to reduce inflammation may translate into a higher LTI. One 
such intervention would be to reduce catheter use because even subclinical 
infections can trigger inflammation30. Another intervention would be timely and 
effective treatment of periodontitis, a frequently neglected source of inflammation31. 
Strategies to improve nutritional competence may include oral supplemental nutrition 
programs.
Strategies to increase creatinine by increasing muscle mass could possibly benefit 
both LTI and FTI32. An unexpected finding of this study is the adverse association 
between high LTI and survival in the simple model, which was only adjusted for age, 
sex, and vintage. Theoretically, underdialysis might explain this10,29,33,34. However,
adjustment for Kt/V did not materially change the results. Adjustment for age, 
vintage, sex, geographic region, albumin, hemoglobin, diabetes, and BP in the 
background predictive models resulted in a loss of statistical significance for high 
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LTIs. This could either indicate a problem of multicollinearity in the extended model 
or a low degree of robustness of the association at high LTI.
This study had certain limitations. The number of patients with high LTI and FTI was 
small (n=36), which could compromise achievement of statistical significance here. 
Prevalent HD patients were studied, and the dialysis vintage at the time of first body 
composition measurement varied between patients. In an attempt to address this we 
adjusted all Cox models for dialysis vintage. MF-BIS by the BCM Body Composition 
Monitor was the sole source of body composition assessment. However, this specific 
methodology has been validated in several studies24-27 (although fat mass was 
validated against gold standard techniques in healthy controls only), and the strong 
relationship to outcome supports the functional validity of the device and its 
measurements. Moreover, the BCM Body Composition Monitor is not able to 
distinguish between appendicular and visceral muscle mass. LTM and adipose 
tissue mass were normalized to height squared for reporting of LTI and FTI, but 
other normalizations could better reflect differences in body compositions between 
races and geographic areas. However, inclusion of geographic area into the model
did not change the results substantially. Also, indexing to height squared is common 
in sarcopenia studies35, and use of this facilitates comparison of study results. BCM 
Body Composition Monitor measurements were performed for clinical reasons, and 
supervising clinicians could use these for interventions (not blinded). However, we 
do not believe that this should be considered a confounder because all clinicians 
followed a common policy (i.e., to target relative overhydration to be <15%); 
therefore, an individual effect may be overruled. Strengths of this research lie in its 
multinational and diverse study population. The fact that this is the largest study on 
this subject conducted so far improves generalizability of the findings. Moreover, the 
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BCM Body Composition Monitor is used on a routine basis, which reduces the 
chances of bias by indication.
In conclusion, this large multinational study demonstrated that LTM and FTM, as 
determined by whole-body MF-BIS, are important predictors of survival in chronic HD 
patients. Both low LTI and FTI, but especially the combination of both, are 
associated with poorer survival. Although BMI values for HD patients are generally 
higher than those for the general population, many patients with apparently 
overweight BMI levels have LTI levels below the 10th percentile of healthy controls. 
These results suggest that routine assessment of body composition by 
bioimpedance adds to the clinical care of HD patients. Trials of interventions to 
maintain lean body mass and fat mass in middle ranges are warranted to further 
explore the relationship between body composition and survival.
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Abstract
Background:
Hyponatremia is a risk factor for mortality in hemodialysis patients. It is not well known to which extent 
the comorbidities, malnutrition, fluid status imbalance and inflammation are related to hyponatremia 
and affect outcomes. 
Methods: 
We studied 8883 patients from the European subset of the international MONitoring Dialysis 
Outcomes initiative. Nutritional and fluid statuses were assessed by bioimpedance spectroscopy. Fluid 
depletion was defined as overhydration ≤ -1.1L and fluid overload as overhydration > +1.1L, 
respectively. Malnutrition was defined as a lean tissue index below the 10th percentile of age- and 
gender-matched healthy controls. Hyponatremia and inflammation were defined as serum sodium 
levels < 135 mEq/L and C-reactive protein levels > 6.0 mg/L, respectively. We used logistic regression 
to test for predictors of hyponatremia and Cox proportional hazards analysis to assess the association 
with all-cause mortality. 
Results: 
Hyponatremia was predicted by the presence of malnutrition (odds ratio (OR) 1.50 (95% CI 1.31-1.71), 
inflammation (OR 1.41 (95% CI 1.24-1.61)), and moderate fluid overload ((> +1.1L to +2.5L) OR 0.86 
(95% CI 0.76 0.65-0.89)), but neither severe fluid overload (> +2.5L) nor fluid depletion (OR 1.31 (95% 
CI 0.90-1.91)). Malnutrition, inflammation, fluid overload, fluid depletion and hyponatremia (hazard 
ratio 1.73 (95% CI 1.48-2.02)) were independent predictors for all-cause mortality. 
Conclusion: 
In hemodialysis patients hyponatremia is associated with malnutrition, inflammation and mild fluid 
overload. Hyponatremia maintained predictive for all-cause mortality after adjustment for malnutrition, 
inflammation and fluid status abnormalities. The presence of hyponatremia may assist in identifying 
hemodialysis patients at increased risk of death.
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Introduction
Hyponatremia has recently emerged as a risk factor for mortality in chronic 
hemodialysis (HD) patients1-3. The association between hyponatremia and mortality 
is not limited to HD patients, but has also been observed in patients with other acute 
and chronic diseases, such as congestive heart failure, pulmonary embolism and 
myocardial infarction4-6. It has been suggested that hyponatremia is associated with a 
“frail phenotype”, given its association with low body mass index (BMI) and 
biochemical markers of malnutrition1,2,7. A relationship between hyponatremia and 
malnutrition has also been observed in other diseases6,8. Hyponatremia may also be 
associated with abnormalities in fluid status, both with regard to fluid overload, as 
well as fluid depletion7,9, or with inflammation, possibly as a reflection of the so called 
“sick cell syndrome”9-11. However, the determinants of hyponatremia in HD patients 
have not been comprehensively addressed, partly because of absence of routine 
measurements of C-reactive protein (CRP) as marker of inflammation and objective 
indicators of body composition and fluid state in previous studies. The paucity of 
research has complicated the interpretation of the relative importance of confounding 
mechanisms when exploring the relation between hyponatremia and outcomes1,8. 
Our study aimed to address that knowledge gap and explore the relationship 
between hyponatremia, nutrition, inflammation and fluid status. We drew on data 
from dialysis facilities where body composition and laboratory markers of 
inflammation are assessed routinely as part of standard of care. The primary goal 
was to determine predictors of hyponatremia, including biomarkers of inflammation, 
fluid status and malnutrition. The secondary goal was to assess the association 
between hyponatremia and mortality with appropriate adjustments for malnutrition, 
fluid status and inflammation.
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Subjects
This retrospective observational study was performed in a European subset of the
international MONitoring Dialysis Outcomes (MONDO) initiative12,13. 
At the time of analysis, MONDO consisted of hemodialysis databases from Renal 
Research Institute clinics in the US, Fresenius Medical Care clinics in Canada, 
Europe, Asia Pacific and Latin America, Kuratorium für Dialyse und 
Nierentransplantation clinics in Germany, Imperial College in United Kingdom, 
Hadassah Medical Center in Israel and Maastricht University Medical Center in The 
Netherlands.
Figure 1: Study flow chart
For this research we only included dialysis facilities in which body composition and 
CRP were determined simultaneously as part of routine care. We considered the 
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routine assessments essential to prevent bias by indication. The final analysis 
included patients from 380 clinics in 17 European countries, namely: Bosnia and 
Herzegovina, Czech Republic, France, Hungary, Ireland, Italy, Poland, Portugal, 
Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Turkey and the United 
Kingdom. Countries were stratified into four regions (Northern, Eastern, Southern and 
Western Europe), based on the United Nations geographic scheme14. Analyses were 
adjusted for these regions because of possible differences in practice patterns. 
Patients with at least one routine body composition measurement, one CRP and 
serum sodium measurement during the baseline year January 1 to December 31, 
2011 were included (Figure 1). The latest body composition measurement in 2011 
served as the start date of a 12 months follow up period (Figure 2).
Figure 2: Study design. All patients of the European subset of the MONDO initiative database with at 
least one whole body multifrequency bioimpedance spectroscopy (MF-BIS) and C-reactive protein 
(CRP) measurement in 2011 were included. Baseline was defined as the 3 months preceding the last 
bioimpedance measurement in 2011, plus the day of that respective MF-BIS measurement. Baseline 
was followed by a 12 monhts period, during which outcomes were noted.
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Averages of clinical and laboratory data collected in the 3 months prior to the body 
composition measurement were used for subsequent logistic regression and Cox 
proportional hazard analyses. Patients consented to the use of their data in 
anonymized form for research in epidemiological studies; absence of that consent
was the sole exclusion criterion. The MONDO database includes information on all 
patients treated in the respective provider network with the data directly extracted 
from the electronic health record systems. Every individual provider has its own 
procedures for data cleaning before data end up in the respective provider system. 
The MONDO database contains only de-identified data. Research conducted by 
MONDO complies with the Declaration of Helsinki. MONDO partner organizations are 
responsible for the primary collection and safeguarding of patient data in accordance 
with all applicable local data protection laws and privacy protection regulations. They 
also ensure full compliance with laws and regulations regarding the secondary use of 
data in the context of MONDO. For data collection and analysis, local ethical, 
compliance, and legal standards are followed12,13. The New England Institutional 
Review Board (IRB) has reviewed the claim of exemption for the study and has 
determined that this research activity is exempt from IRB review. 
Methods 
Determination and definition of fluid status and body composition 
We used the body composition monitor (BCM; Fresenius Medical Care, Bad 
Homburg, Germany) to assess body composition and fluid status. The BCM is a 
whole body multifrequency bioimpedance spectroscopy (MF-BIS) device that has 
been validated against gold standard techniques in HD patients15-17. The BCM 
mortality, hyponatremia, inflammation and malnutrition in hemodialysis patients
143
reports overhydration (OH) as a separate compartment in reference to 
normohydration. We defined normohydration as pre-dialysis OH in a range of -1.1 to 
+1.1L around normohydration. These thresholds were chosen according the 
hydration reference plots provided by the manufacturer, based on the reference 
values for normohydration as derived from the 10th and 90th percentiles in the healthy 
population 18. Fluid depletion was defined as pre-dialysis OH ≤ -1.1L, moderate fluid 
overload as pre-dialysis OH > +1.1L to +2.5L and severe fluid overload as pre-
dialysis OH > +2.5L to +5.0L. Definitions of the fluid overload groups were chosen 
according to literature19. We accounted for differences in body-phenotype by 
adjusting for body surface area (BSA), calculated by the Du Bois Formula, BSA (m2) 
= 0.007184 x (pre-dialysis weight (kg))0.425 x (patient height(cm))0.725 20.
Malnutrition was defined as a lean tissue index (LTI) below 10th percentile of age and 
gender matched healthy controls. BCM reports the LTI, which is lean tissue mass 
normalized to the height in meters squared, and also age- and gender-matched LTI 
percentiles. Fat tissue index (FTI), also assessed by BCM, was included as an 
additional independent parameter in the Cox regression model. LTI was chosen as 
the prime nutritional parameter because derangements in lean tissue mass are 
expected to have larger effects on sodium distribution as compared to changes in fat 
mass. 
Definition of hyponatremia and inflammation
In agreement with the literature2,21, hyponatremia was defined as a pre-dialysis 
serum sodium level below 135 mEq/L. Serum sodium was measured using standard 
indirect ionometry. Inflammation was defined as CRP levels > 6.0 mg/L22-24. Serum 
glucose levels were not routinely available at the time of sodium measurements.
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Statistical analysis
Continuous variables are reported as mean ± standard deviation (SD), or median and 
25th-75th percentile depending on their distributions. Logistic regression models with 
adjustment for age, gender, dialysate sodium, dialysis vintage, access (arterio-
venous versus catheter access), region, body surface area (BSA) diabetes mellitus 
and congestive heart failure, were used to analyse predictors of hyponatremia. Cox 
proportional hazards models with adjustment for inflammation, malnutrition, fluid 
status abnormalities, age, gender, dialysate sodium concentration, dialysis vintage, 
diabetes mellitus, congestive heart failure, cerebrovascular disease, peripheral 
vascular disease and presence of a malignancy, were developed to assess the 
association between hyponatremia and mortality. We constructed both a basic Cox 
model, including only LTI as a parameter of nutrition, and an extended Cox model 
including also systolic blood pressure, normalized protein catabolic rate (nPCR) and 
serum albumin levels. We report point estimates and 95% confidence intervals (CI) of 
the odds ratios (OR) and hazard ratios (HR). Censoring events were transfer to 
another dialysis facility, kidney transplantation, recovery of renal function, modality 
change, or the end of study on December 31, 2012. Differences between patients 
with and without hyponatremia were analysed by independent samples Student t-
test, Mann-Wittney U Test or Pearson chi square analyses, as appropriate. 
Computations were performed with SAS version 9.3 (Cary, NC, USA) and R statistics 
software system version 3.0.2.
Results 
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Prevalence and predictors of hyponatremia
We included 8883 patients, their demographic characteristics, body composition and 
dialysis treatment characteristics are shown in Table 1.
Patients’ median age was 63 years, 57.2% males, and median dialysis vintage was 
3.6 years. Median serum sodium was 138 mEq/l (136–140), and 1129 (12.7%) 
patients were hyponatremic. Significant predictors for hyponatremia were malnutrition 
(OR = 1.49 (95% CI = 1.30–1.70)) and inflammation (OR = 1.44 (95% CI = 1.26–
1.64)). Fluid overload, moderate (>+1.1 l to +2.5 l (OR = 0.73 (95% CI = 0.62–0.85))) 
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and severe (>+2.5 l to 5.0 l (OR = 0.79 (95% CI = 0.65–0.94)), was associated with a 
protective effect, whereas fluid depletion (OR = 1.34 (95% CI = 0.92–1.96)) was not 
predictive for hyponatremia (Table 2). Diabetes was more prevalent in hyponatremic 
patients (29.5% vs 17.0%; Po0.001). CRP levels were higher in hyponatremic 
patients (7.0 vs 5.43 mg/l; Po0.001; Table 1). Mean dialysate sodium was 139 mmol/l 
(s.d. 1.81) in the ‘normal’ group and 138 mmol/l (s.d. 2.06) in the hyponatremia 
group. The sodium gradient (calculated as dialysate sodium minus plasma sodium
level) was higher in the hyponatremia group (median 5.33 mmol/l (3.67–7.0 (25th–
75th percentile))), compared with the group without hyponatremia (median 0.00 
mmol/l (−2.00 to +2.00 (25th – 75th percentile))).
Hyponatremia and mortality
In multivariate analysis, hyponatremia, malnutrition, inflammation, moderate and 
severe fluid overload and fluid depletion were associated with mortality (Table 3). 
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The extended model yielded materially identical results with respect (Table 4) to 
hyponatremia (HR = 1.65 (95% CI = 1.40–1.95)), malnutrition (HR = 1.49 (95% CI = 
1.23–1.81)), inflammation (HR = 1.87 (95% CI = 1.62–2.16)), and the various fluid 
status groups, fluid depletion < − 1.1 l (HR = 1.86 (95% CI = 1.20–2.91)), moderate 
fluid overload (>+1.1 to +2.5 l; HR = 1.65 (95% CI = 1.36–2.00)) and severe fluid 
overload (>+2.5 to +5.0 l; HR = 2.44 (95% CI = 1.99–3.00); Supplementary Material).
Discussion
This study resulted in two main insights. First, we found a robust association between 
hyponatremia, malnutrition and inflammation. Second, hyponatremia remained a 
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significant predictor of death in Cox models with adjustment for malnutrition, 
inflammation and deranged fluid status. 
Our study adds to the literature by including objective indices of body composition, 
malnutrition and fluid status determined in a large multinational dialysis patient 
cohort. In contrast, previous studies employed primarily biochemical nutritional 
markers1,2. We defined malnutrition as LTI below the 10th percentile of age and 
gender matched healthy subjects, reflecting more protein energy wasting25. In a 
previous study, low LTI assessed by bioimpedance, was highly predictive of 
mortality26. The LTI measured by the BCM is not influenced by fluid overload, which 
is expressed as a separate compartment in a 3-compartment model15,16. Although 
various means allow the diagnosis of malnutrition in dialysis patients27, we prefer LTI 
as a standardized and objective indicator of somatic phenotype, as the main 
nutritional marker. However we used several statistical models to assess the 
association between hyponatremia, malnutrition and mortality. In the basic model, we 
deliberately did not include other parameters of malnutrition because of potential co 
linearity with either CRP or LTI. However, the extended model which included these 
parameters, namely, albumin, FTI and nPCR, showed materially identical results.
The pathophysiology of the relation between malnutrition and hyponatremia is being 
quite intensively discussed1,2,7. Insufficient intake of sodium or excess of free water 
intake in anuric patient, but also the derangements in body composition itself, could 
contribute to this phenomenon. Flear et al. observed differences in the relation 
between muscle water and serum sodium in seven patients suffering from a variety of 
diseases28. They observed a higher sodium-to-water ratio, suggesting an abnormal 
electrolyte distribution, although the relation to serum sodium was not analysed28. In 
addition, catabolism of organic phosphates in the intracellular compartment (IC) could 
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result in the excretion of inorganic phosphate and potassium into the extracellular 
compartment (EC), accompanied by a concomitant water shift from the IC to the 
EC29. An increased water shift from the IC to the EC could also be explained by 
defective cell membrane integrity, allowing movement of intracellular solutes to 
extracellular water compartment. Both mechanisms have been described in the “sick-
cell syndrome”, a rather controversial condition30. 
Inflammation was associated with hyponatremia independent from the presence or 
absence of malnutrition. Data are limited regarding the relation between inflammation 
and serum sodium in dialysis patients. Hecking et al. observed an inverse relation 
between white blood cell count and serum sodium levels in their cohort2. 
Interestingly, hyponatremia was associated with infection-related mortality in HD 
patients, and is frequently associated with other inflammatory diseases3. It has been 
suggested that either hyponatremia per se, or by mucosal barrier breakdown through 
cellular edema, could stimulate inflammation3. Also, non-osmotic storage of sodium 
may induce the synthesis of interleukin-17 by CD4+ T-helper cells, which may 
contribute to chronic systemic inflammation31. 
Another potential cause of hyponatremia, explored in the present study, is sodium 
dilution due to fluid overload. In congestive heart failure dilutional hyponatremia 
frequently occurs, which is related to an increased release of copeptin, vasopressin 
and impaired renal free water excretion4,9,32. Whereas this mechanism is absent in 
anuric HD patients, dipsogenic factors such as angiotensin II, could contribute to 
increased thirst 33,34; of note, an inverse relation between interdialytic weight gain and 
pre-dialysis sodium has been observed1,2. In the present study we found moderate 
fluid overload (pre-dialysis OH > +1.1L to +2.5L) to be associated with a decreased 
change on hyponatremia. Although we suggest that this might be due to the isotonic 
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increase in body fluid with a good appetite, we acknowledge that this hypothesis is 
still conjectural. Dialysate sodium levels were slightly lower in patients with 
hyponatremia as compared to patients with normal serum sodium levels. However, 
the sodium gradient (difference between dialysate and serum sodium) was higher in 
the hyponatremic patients, with likely higher diffusive sodium gains in hyponatremic 
patients35. From the present database, it cannot be concluded whether the lower 
dialysate sodium is a cause or consequence (e.g. due to individualization of the 
dialysate) of lower pre-dialytic serum sodium levels.  However, large cohort studies 
did not observe a significant correlation between both variables in large cohort 
studies36,37. Possibly, higher dialysate-serum sodium gradients may lead to increased 
water intake in the inter-dialytic period, in order to compensate for the diffusive 
sodium gain and plasma tonicity during dialysis, leading to increased inter-dialytic 
weight gain without a change in serum sodium38. Additional factors, most notably 
diabetes, were associated with hyponatremia, corroborating previous studies39.  
Unfortunately, we do not have availability of serum glucose and HbA1C 
measurements on a routine basis in the present database. 
Despite its strong association with malnutrition and inflammation, hyponatremia 
remained an independent risk factor for mortality after adjustment for nutritional 
status, inflammation and fluid overload. This finding corroborates previous studies 
employing biochemical parameters or BMI as nutrition markers1,2. Our study expands 
on these reports by providing detailed measures of body composition, and CRP 
levels. Since all these results are observational, we cannot address the question 
whether hyponatremia per se is causally related to mortality, or whether this 
observation is due to residual confounding40,41. 
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We recognize that our study has limitation beyond its observational nature. First, 
bioimpedance and laboratory studies were not always done concurrently. Therefore 
we used time averaged values over a short baseline period to mitigate this problem. 
We able to use data of 25% of the entire cohort, due to the fact that both 
bioimpedance measurements, serum sodium and CRP measurements had to be 
performed within these predefined limits. Although bioimpedance measurements are 
used on a routine basis in the cohort, we cannot exclude some selection bias in our 
study due to the fact that measurements might also have been performed on an 
additional clinical indication.  Second, one could argue that thresholds e.g. for sodium 
and CRP are arbitrary. However, we deliberately chose clinically useful cut-off limits 
to improve clarity and to relate to literature2,21-24,42. Third, while serum sodium levels 
are strongly influenced by hyperglycemia43, concurrent measurements of glucose and 
sodium were not routinely available. To alleviate that shortcoming, we adjusted for 
the presence of diabetes, which - not unexpectedly - turned out to be a risk factor for 
hyponatremia and to be associated with outcome39. Forth, we lack reliable data on 
residual renal function, a potential determinant of pre-dialytic serum sodium2. In 
conclusion, malnutrition and inflammation, and moderate pre-dialysis fluid overload, 
but not severe fluid overload nor fluid depletion, were associated with hyponatremia 
in a large multinational HD patients cohort. Importantly, even after adjustment for 
these parameters, hyponatremia remained a significant predictor of mortality. 
Whether hyponatremia and outcome are causally related or a mere reflection of 
residual confounding cannot be concluded from this study. However, next to markers 
of inflammation, malnutrition and fluid status, serum sodium appears to be an 
important clinical parameter relevant for the care of HD patients.
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General discussion
The first aim of this thesis was to clarify the reason for the improved survival in 
obese end-stage renal disease (ESRD) patients, which is different from the general 
population where obesity is a cardiovascular risk factor. Since obesity is defined by 
the ratio of body weight to height squared, it is also important to differentiate its 
components. Therefore, the relation between fat mass, lean tissue mass and 
outcome was investigated. 
The second aim was to assess the dynamics of nutritional parameters, including 
body composition, following the start of dialysis treatment. This is of importance as 
dialysis treatment may have both beneficial and adverse effects on nutritional state, 
whereas the available data on this subject are both limited as well as controversial. 
Abnormalities in nutritional state have various correlates in ESRD patients. Whereas 
the relation with inflammation is well established, hyponatremia appears to be an 
emerging risk factor for mortality which is both associated with inflammation and 
nutritional abnormalities. However, there are limited data on this relation in ESRD 
patients. Therefore, the third and last aim dealt with the relationship between 
nutritional status with inflammation and hyponatremia.
As reported in chapter 2, higher body mass index in the range of overweight and 
obesity was associated with better survival in a large prospective Southern European 
cohort of patients on hemodialysis (HD)2. This paradoxical association of obesity and 
even morbid obesity with improved outcome was confirmed by several studies not 
only in patients with ESRD but also in patients with other chronic diseases3,4, 
including chronic heart failure5. However, the categorization of patients according to 
nutritional status as defined by body mass index (BMI) is a strong limitation of this 
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large mass of medical research. In fact, as deeply discussed in chapter 2, this index 
created by Quetelet6 in 1835 is based on an inexact assumption about the 
distribution of body mass between muscle and fat. BMI has the tendency to 
overestimate adiposity in those with more lean body mass, e.g. athletes, and to 
underestimate excess adiposity on those with less lean body mass. The risk of  such 
a misclassification is particularly high in the intermediate level between 20 and 30 
kg/m2, which is associated with a wide range of body fat percentages7. In addition, 
as recently highlighted by Carrero et al8, BMI does not capture the aging changes in 
body composition, the gender-variation in body shape,  and the difference between 
central and peripheral fat accumulation. Finally, BMI is falsely increased by fluid 
overload, which is very important in patients on dialysis. Therefore, the conclusion of 
chapter 3 was that considering the intrinsic limitations of all nutritional markers, a
multi-perspective approach with a combination of measures and a stepwise 
procedure is recommended9. The first step for the purpose for screening and early 
detection of malnutrition is to use subjective clinical assessment, relying on validated 
subjective global assessment (SGA)10. The second is the assessment of the body 
composition by bioimpedance spectroscopy with the physiological model for 
quantifying and ensuring follow-up of patients at risk of malnutrition or for monitoring 
patients with already established protein-energy wasting, as discussed in chapter 4
and 7. The third step is to deal with the use of routine laboratory parameters, such as 
albumin or CRP for monitoring inflammation level, as discussed in chapters 5 and 6. 
The verification of a medium to long term improvement of patients with compromised 
nutritional status after the initiation of a proper nutritional therapy or other important  
interventions, such as the start of dialysis treatment, would be a major  benefit. In 
fact, as shown in chapter 2 patients losing more than 5.8% of the initial body weight 
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are those with the higher risk of death. It is likely that this subgroup is composed of 
patients whose loss in lean tissue is not balanced by an increase in fat tissue, as 
pointed out in chapter 4. This subgroup should be the main target of a nutritional 
therapy but, as discussed, results cannot be judged only on the basis of a proportion 
of recovery in body weight. 
In bioimpedance spectroscopy with physiological model technique, the extra- and 
intra-cellular water compartments are calculated using the Hanai and Cole 
model11,12. Additionally, using the physiological model based on normohydrated 
tissue properties13, it is possible to distinguish fluid overload from muscle mass. The 
importance of estimating a proxy to muscle mass has been recently recommended 
by the ESPEN consensus statement14, advocating the general use of body 
composition measurements in all health care settings, i.e. in primary care, in nursing 
homes, and  home elderly care. Recently, the National Health and Nutrition 
Examination Survey (NHANES)15, reported results on the association between 
sarcopenia (defined as appendicular skeletal muscle mass index <5.45 kg/m2 in 
women and <7.26 kg/m2 in men) and chronic kidney disease (CKD) stages of 11643 
subjects who underwent dual-energy X-ray absorptiometry (DXA) evaluation. The 
main result was an almost linear association between the increasing proportions of 
patients with sarcopenia with more advanced stages of CKD.
Therefore, loss of muscle mass is commonly observed  among CKD and dialysis 
patients, but since muscle mass normally declines with age with gender specific 
trajectories, a consensus criteria has to be developed in order to properly classify 
patients17. In the absence of such diagnostic criteria, in chapter 7 patients with lean 
tissue index (LTI; lean tissue mass/height2) and fat tissue index (FTI; fat tissue 
mass/height2)   measured using bioimpedance were compared with the distribution in 
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age and sex-matched healthy controls. Patients with LTI or FTI values below the 10th
percentile were considered as low LTI or FTI patients, respectively. Similarly, those 
patients with LTI or FTI values over the 90th percentile of the distribution in age and 
sex-matched healthy controls were considered high LTI or FTI patients, respectively. 
In summary, chapter 7 showed that LTI and FTI within the 10th–90th percentile of 
an age- and sex matched healthy population were associated with the best survival,
whereas low FTI and low LTI, and especially the combination of both, were 
associated with higher mortality18. Skeletal muscle accounts for about 40% of body 
weight and 50% of the body protein19 and is the major protein physiological reserve 
of the body, used when renal function declines. Muscle mass decreases when 
protein or amino acids are needed because, contrary to fats, excess proteins are not 
stored, and protein balance is physiologically based on sufficient protein intake. In 
cases of inadequate protein intake, the priority will be on the maintenance of critical 
metabolic functions, even sacrificing muscle mass. Therefore, a low level of muscle 
mass may indicate that the protein reserves are already exhausted and that these 
critical functions cannot be ensured anymore, explaining the reported association 
between low LTI and mortality20. Regarding the fat tissue, fat it is the largest energy 
reserve in mammals. Adipose tissue is involved in fatty acid metabolism, with a store 
of triacylglycerol that can be hydrolyzed in a regulated way to directly release fatty 
acids into the circulation for delivery to other tissues21. The presence of a fat tissue 
energy reserve can prevent an additional catabolic stress to the muscle, from the 
quantitative point of view the second tissue involved in the metabolism of fatty acid21. 
However, the protective effect of normal and even high FTI appears to be somehow 
contradictory since the pro-inflammatory properties of fat, mainly visceral, have been 
demonstrated in the general population. Finally, it has to be stressed that fat may be 
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associated with greater secretion of anti-inflammatory cytokines than pro-
inflammatory molecules in dialysis patients22,23. 
The start of dialysis treatment is a major transition in the life of a patients of ESRD. 
Starting dialysis treatment can have both beneficial as well as adverse effect on 
nutritional state. longitudinal studies, should capture this close association. Chapter 
4 showed that, following the transition to HD, ESRD patients presented with 
distinctive changes in body composition, namely with a decrease of 0.40 kg/m2 of 
lean tissue index (LTI) and a parallel increase of 0.95 kg/m2 of fat tissue index 
(FTI)24. These were mainly associated with gender, older age, presence of diabetes, 
low baseline FTI, and high baseline LTI. As expected, BMI increases of about 0.60 
kg/m2 did not fully represent the changes in body composition.
Albumin is a marker of visceral protein, inflammation and overhydration25. Low 
albumin levels not only mean low oncotic pressure, with water shift between the 
intravascular and interstitial space, but may also be associated with increased blood 
viscosity26 and hypercoagulable states27. Finally, reduced albumin binding capacity 
for drugs and endogenous ligands is a characteristic of CKD28. The association with 
negative outcome in patients having low albumin levels is well known. However, 
since low albumin levels can be the result of different processes, it is not clear if the 
outcome is causally related or if albumin is just an indicator of events associated with 
increased mortality. Creatinine generation is proportional to dietary meat intake and 
mainly to somatic protein mass, with higher levels in those patients whose superior 
nutritional status sustains an increased musculature. Finally, creatinine, similarly to 
albumin, has been found to be a strong predictor of mortality risk.29 The study 
reported in chapter 5 evaluated the development of the level of albumin and 
creatinine in the initial phase of dialysis, with the aim to maximize the benefit of 
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laboratory measurements normally available from the routine continuous 
assessment. Evaluating 2 years from baseline to 27 months after initiation of 
dialysis, a significant increase in serum albumin of 0.15 ± 0.45 g/dL was found using 
delta analysis. Of note, the serum albumin increased most significantly in the first 6 
months. During the first months on HD many factors can play roles and act in 
opposite directions. For example, in patients with significant proteinuria, the loss of 
residual renal function (RRF) will decrease albumin loss. In fact, after 3 months from 
the initiation of HD, because of a policy of strict volume control applied in the dialysis 
network as evidenced by the low post-dialysis fluid overload (0.16±2.13 liters), 
residual diuresis is expected to be negligible30. In parallel, hemoconcentration 
(resulting from the achievement of a lower hydration status) would increase albumin 
levels. Finally, with the initiation of renal replacement therapy (RRT), dietary protein 
intake is expected to improve while the loss of amino acids through the dialysis 
membrane may negatively affect the protein balance. It has to be stressed that 
patients with C-reactive protein (CRP) ≥10 mg/dL had significantly lower albumin (-
0.1355 mg/dL difference, p-value<0.001), but had a significantly higher albumin 
increase over the follow-up time (by 0.07 mg/dL per year, p-value<0.001). No 
significant effect was found for creatinine, neither for the main effect of CRP nor for 
the interaction term. The conflicting trends of lean body mass and albumin following 
the initiation of dialysis deserve further comments. It is clear that serum albumin 
cannot be considered the best marker to verify nutritional status because it is not 
only a marker of visceral protein but also of inflammation and overhydration25. Gama 
Axelsson et al31 clearly demonstrated that serum albumin is a weak predictor of 
nutritional status as defined by SGA scores, with association between serum 
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albumin and other markers of nutritional status such as handgrip strength and lean 
body mass being even weaker.
The relationship between inflammation and albumin as a biochemical marker for 
malnutrition was more deeply discussed in chapter 6. CRP is clinically the most 
popular inflammatory marker routinely used. It is an acute phase reactant, chemically 
stable and with a relatively long half-life without diurnal variation. However, 
neutrophil-to-lymphocyte ratio (NLR) is becoming increasingly more recognized as a 
marker of systemic inflammation in oncology and in cardiology32,33, and finally also in 
CKD patients34. Oxidative stress and inflammation are both known to inhibit albumin 
synthesis35,36, and they are often present in dialysis patients37,38. In the study 
reported in chapter 6, serum albumin levels were negatively correlated with both 
NLR and CRP39. These findings are consistent with the hypothesis that albumin 
behaves as a negative acute phase protein and also support the concept of 
malnutrition-inflammation complex in patients on dialysis40.
An emerging risk factor in dialysis patients is the presence of hyponatremia (defined 
as a serum sodium below 135 mmol/l). Waikar et al reported an association of low 
predialysis serum sodium concentration with an increased risk of death41. In principle 
this observation is not surprising since hyponatremia is very often associated with 
several medical conditions, including congestive heart failure42 and cirrhosis43. In 
patients with congestive heart failure and cirrhosis, hyponatremia partially derives 
from high arginine vasopressin levels, which are directly correlated with the severity 
of heart failure and liver disease. In these conditions, hyponatremia is mediated by 
the non-osmotic release of arginine vasopressin and a reduced free water clearance
by the kidney, which in turn may reflect the severity of the underlying disease 
process through mechanisms such as reduced glomerular filtration rate and 
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activation of the sympathetic nervous system. However, a relationship between 
hyponatremia and malnutrition was already observed in other diseases44. Waikar et 
al41 excluded the possibility that the analysis may be confused by cachexia and 
malnutrition because of adjustment with measures of dietary intake. This conclusion 
was discussed by Lin et al45, who noted that patients with hyponatremia in the first 
quartile of the distribution of baseline predialysis serum sodium concentration had 
the lowest estimated dry body mass index and creatinine level. This reflects a 
malnutrition status and was associated with a higher death rate in a maintenance 
dialysis population. In line with Lin’s opinion, results reported in chapter 8 confirm a 
robust association between hyponatremia, malnutrition and inflammation. An 
additional association was found with moderate fluid overload, but not with severe 
fluid overload or fluid depletion. Similarly to the findings of Waikar et al41, it was 
found that hyponatremia remained a significant predictor of mortality even after 
adjustment for these parameters.
In conclusion, with this thesis the importance of disease-related malnutrition14 - or 
more precisely protein-energy wasting - regarding the outcome of dialysis patients 
has been confirmed. Moreover, the paradoxical association between obesity and 
improved outcome has been explored in more detail using more detailed 
assessment of body composition in large international cohorts of dialysis patients.   
Protein energy wasting is very frequent and develops over time after admission to 
RRT. Several factors are associated with malnutrition, including inflammation and 
hyponatremia. However, whether they are causally related or not cannot be definitely 
concluded by this study. Regarding future research, a move from body weight, 
normalized or not for squared height, to body composition1 would surely open new 
promising fields. In fact, the availability of a simple, inexpensive and easily 
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repeatable technique able to estimate lean and fat body mass means that a powerful 
surrogate outcome is available to test all new therapeutical options in the 
management of chronic diseases. For example, it is possible to make comparisons 
not only between different dialysis modalities but also between intensities of 
treatment (standard vs. frequent or long HD).
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Valorization
The collection of manuscripts included in this thesis highlights the high prevalence of 
protein-energy wasting in patients on hemodialysis and its relationship with mortality. 
Additionally, the dynamics of the development of malnutrition during the first 30 
months on dialysis treatment were clarified. Therefore, the problem of malnutrition is 
clear and it is likely to be at least partially responsible for the high risk of clinical 
complications during the follow-up, associated with a significant component of the 
total cost burden of the disease due to hospitalization costs.
However, in front of a clear need to improve the nutritional therapy of patients on 
hemodialysis, as recently stressed by Hand et al1, in US a dietician has to follow 
about 150 patients and the focus is mainly on mineral and bone disorder. Dieticians 
spend more checking phosphate intake and compliance to phosphate binders. It is 
not the aim of this chapter to judge the importance of this specific complication, but 
the evidence that today in US the yearly pharmaceutical budget spent for mineral 
and bone disorder is about 30-fold higher than that of parenteral nutrition is 
impressive2. In absence of clear data, the general opinion is that the US situation is
common with many other countries.
Protein-energy wasting should be prevented, or at least detected and also followed-
up after start of renal replacement therapy in a very early phase according to a 
judicious choice of methods discussed in this thesis, in combination with a serious 
nutrient intake assessment and consequent dietary advice. However, it is well known 
that the change of the nutritional habits is one of the hardest tasks, and requires 
competence, dedication and time of experience dieticians, nephrologists and dialysis 
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nurses. Patients have to be strictly followed-up, educated on the benefit of 
maintaining proper dietary standards. It is a matter of fact that patients starting 
dialysis after a pre-dialysis phase on low protein diet do not present major nutritional 
problems and are likely more compliant to dietary advices3. Patient empowerment is 
clearly a strong tool in the hands of nephrologists to improve the outcome of patients 
on dialysis, and it is expected to be very cost-effective. However, it is clear that the 
very limited resources in term of available dieticians will not allow an efficient 
realization of this strategy. But whereas in US and other countries (e.g. France, 
Portugal, UK) the discussion is on the limited number of renal dieticians available, at 
least they are mandatory members of the team taking care of dialysis patients. In 
other countries their presence is even considered as optional and close collaboration 
between dialysis and dietetic staffs remains essential to handle this challenge. Web 
based educational tools may become in future effective approaches, but the current 
generation of patients will hardly benefit.
The uncover of a progressive protein-energy wasting disease should also trigger the 
search for hidden foci of infection/inflammation, facilitating the earlier reclaim. 
Since nutritional therapy is so important in the follow-up of renal patients before and 
after the initiation of renal replacement therapy, it should be an important component 
of the education of nephrologists, so improving the communication with renal 
dieticians. Quality indicators related to the regular and frequent performance of 
nutritional assessment and of the obtained results in term of corrected nutritional 
habits should be part of the follow-up of dialysis patients. Likely, this should be the 
next logic development as the system of reimbursement for the treatment of dialysis 
patients is moving to total capitation4, in future including also cost of hospitalization. 
If it is true that nutritional secondary prevention is cost effective in avoiding or 
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delaying certain complications requiring expensive hospitalizations, providers of 
dialysis care will quickly move to implement a strong nutritional follow-up and therapy 
in their treatment protocols.
In conclusion, the research manuscripts included in this thesis supports a change in 
the management of patients on dialysis, with more focus on the nutritional aspects 
and the implementation of therapeutical measures able to prevent or correct in early 
phase protein-energy wasting. More research is required to define which therapy is 
more effective, and appropriately designed randomized clinical trials are urgently 
needed.
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30 years' diverse leadership experiences in Nephrology (University of Modena 
Certification) with significant accomplishments in organizing dialysis care process 
(i.e. see publications 63, 67, 83, 115) derived from 10 year experience in the 
nephrological ward and in the kidney transplantation outpatient follow-up (Hospital 
Manzoni, Lecco, Prof. Locatelli) and 20 years in medical device companies vertically 
integrated with dialysis service (Fresenius Medical Care, Bad Homburg, Germany
and B. Braun Avitum, Melsungen, Germany).
The key points of my curriculum in renal care were related to scientific research, 
healthcare organization managements, dialysis medical device and renal 
pharmaceuticals. 
In the research field, I started my career as technician in the chemical lab in CRTN, 
the research division of ENEL, at that time the monopolist Electric Energy producer 
in Italy, with involvement in a project funded by the European Economic Community 
(EEC) aimed at evaluating an innovative efficient multi-flash process in producing 
pure water from sea water. After medical graduation and the degree in Medical 
Statistics (University of Pavia) I remained in the research field publishing several 
papers in the field of progression of chronic renal failure and in dialysis (outcome and 
cardiovascular complication of ESRD diabetic and non-diabetic patients), being 
involved in the design, analysis and finalization of manuscripts on randomized 
clinical trials. However, large part of the research activity was conducted as 
epidemiological research, using existing databases (Lombardy Dialysis Registry, US 
Renal Data System) and an ad-hoc renal Database (EuCliD, European Clinical 
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Database), developed according to my input. As result 141 publications in peer-
review journals have been accomplished, in the field of: Medical device validation 
and application, Epidemiology, Healthcare management, Health economics, 
Nephrology, Cardiology, Nutrition and Hypertension. My Hirsch index is 29 (Google 
scholar). I also served several scientific journals as reviewer (Nephrology Dialysis 
Transplantation, J of Nephrology, British Medical Journal, Int J Artificial Organs, etc).
In the field of dialysis medical device, I was involved in the design of the study 
proving the superiority of high-flux membranes (ref. 14, 23), in epidemiological 
analysis supporting the evidence of the superior outcome of convective therapies 
(ref. 35, 109) and in the validation of components of the dialysis equipment: blood 
temperature monitor (ref. 38), on-line clearance measurement (ref. 52), tool for the 
maximization of convective dose in online HDF (ref. 113, 125).
In the pharmaceutical environment I cooperated with different Pharma companies 
(Ciba-Geigy, Glaxo, Amgen, Sigma-Tau) in generating research protocols, analysing 
data from clinical trials, organizing and managing steering committees and finalizing 
manuscripts aimed to evaluate the impact of different therapies on outcome (i.e. ref 
79).
Clinical governance and in general healthcare management is one of the topic I was 
mainly involved, being also MBA certified on International Hospital and Healthcare 
Management (Frankfurt school of Finance and Management). More in details, I was 
Responsible for Clinical Governance of the NephroCare Dialysis Clinics Network in 
Europe, Middle East and Africa for more than 500 dialysis clinics located in 23 
countries (about 50,000 patient), leading a team of professionals in the field of 
dialysis, nursing, data analysis, clinical risk management and working within a matrix 
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organization with the Country Medical and Nursing Directors of all related countries 
(additional 46 people). The activity required the implementation of Practice Medical 
Guidelines, the development of standards operating procedures (SOPs), the 
provision of GCP (“Good Clinical Practice”) trainings, and the preparation of internal 
and external audits. Additionally, with my contribution a Crisis response organization 
for the same geographical area was founded.
In healthcare policy, I was a member of the Dialysis Registry commission of the 
Regional Healthcare Authority of Lombardy (Italy), and then I followed up the 
reimbursement issues of different National Healthcare Authorities, initially focusing 
on premium price for innovative therapies (i.e. see publication on HTA evaluation 89 
and on cost-effectiveness 126 and 139) and then on new reimbursement policies 
(from bundled reimbursement to full capitation, see publication 93).
As physician, I still have strong motivations to play a role not only in the scientific 
world but also on educational activities for the population. For this reason from 2012 
to 2016 I cooperated with the Journal “Corriere d’Italia”, published in Germany for the 
Italian Community (30,000 copies per issue). Every month a patient-empowerment 
like articles on different relevant topics for elderly people was published.
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